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Matrix Metalloproteinase genes are transcriptionally regulated by E2F 
transcription factors: a link between cell cycle control and metastatic 
progression 
 
Abstract 
The Rb-E2F transcriptional regulatory pathway plays a critical role in the 
cell cycle. Rb is inactivated through multiple waves of phosphorylation, mediated 
mainly by cyclin D and cyclin E associated kinases. Once Rb is inactivated, cells 
can enter S-phase. Collectively, three Rb family members and ten E2F proteins 
coordinate every additional stage of the cell cycle, from quiescence to mitosis. 
However the Rb-E2F pathway is frequently altered in cancer. Aside from cell 
proliferation, the Rb-E2F pathway regulates other essential cellular processes 
including apoptosis, cell differentiation, angiogenesis and DNA damage repair 
pathways, but its role in invasion and cancer progression is less clear. We 
demonstrate here that matrix metalloproteinases genes (MMPs), which regulate 
the invasion, migration and collagen degradation activities of cancer cells during 
metastasis are transcriptionally regulated by the Rb-E2F pathway. Unlike E2F 
target genes involved in cell proliferation, which are solely regulated by the E2F 
activators (E2F1-3), additional E2F family members can regulate MMP9, 
MMP14, and MMP15. While we had previously shown that Raf-1 kinase 
physically interacts with Rb, and that disruption of this interaction with a small 
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molecule inhibitor of the Rb-Raf-1 interaction (RRD-251) can inhibit cell 
proliferation, angiogenesis, and growth of tumors in mouse models, we now 
show RRD-251 inhibits the expression of MMPs and the biological functions 
mediated by MMPs as well—including invasion, migration, and collagen 
degradation. RRD-251 also inhibits metastatic foci development in a tail vein lung 
colonization model in mice. These results suggest that E2F transcription factors 
may play a role in promoting metastasis through regulation of MMP genes. 
Conversely, another MMP gene connected to metastasis, MMP2, is 
transcriptionally repressed by E2F1 in lung cancer cells through a p53-KAP1-
HDAC1-mediated mechanism. However, E2F1 cannot repress the MMP2 
promoter in cells that are lacking any component of this complex, such as p53 
mutant breast cancer cells. Therefore the role of the Rb-E2F pathway in MMP 
transcription and metastasis is cell type dependent. In addition to growth factors, 
nicotine can also induce cell proliferation, angiogenesis, EMT, and progression of 
lung cancer. In our studies, nicotine induced invasion, collagen degradation, and 
transcription of MMP2, MMP9, MMP14, and MMP15 required nAChRs, and 
multiple E2F family members. Our studies also show that nicotine not only 
promotes tumor growth in vivo through the nAChR-E2F pathway—it also results 
in metastasis to the liver and brain. Taken together, these studies link the Rb-
E2F pathway to the regulation of many facets of cancer. 
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Chapter 1: Introduction 
 
1.The retinoblastoma gene 
The speculation that humans likely carried genes which protected normal 
cells from becoming malignant was proposed long before the cloning of the first 
tumor suppressor gene.  The retinoblastoma gene,  Rb1 or Rb,  was the first 
tumor suppressor to be identified and subsequently cloned (1, 2).  Studies 
following the inheritance patterns of a pediatric tumor of the retina, which 
primarily occurs in children between 9 months and 5 years, showed that deletion 
or mutation of chromosome 13q14.1-13q14.2 could result in retinoblastoma, and 
patients could also be victim of a secondary non-ocular tumor such as 
osteosarcoma (2, 3). These studies also pointed out that mutation or deletion of 
the Rb gene could be hereditary or arise during gametogenesis. The familial form 
of retinoblastoma is bilateral and multifocal, whereas the sporadic form is 
unilateral (2).  Taken with Alfred Knudson’s observation that two distinct genetic 
“hits” must occur thereby initiating cancer, these studies are the foundation for 
the current tumor suppressor paradigm.  
 
 Rb was cloned by chromosome walking from Esterase D, a gene that was 
linked to the retinoblastoma susceptibility locus. The Rb gene encoded a 928 
amino acid nuclear phosphoprotein with weak DNA binding activity (4).  It 
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was found that Rb protein could form stable protein-protein complexes with viral 
oncoproteins of adenovirus E1A and SV 40 large T-antigen, both of which cause 
tumors in rodents, in addition to the human papilloma virus (HPV) E7, which 
causes cancers in humans (5, 6). This led to the hypothesis that the Rb gene did 
not have to be mutated or deleted, but the Rb protein could also be inhibited by 
viral proteins to abrogate its tumor suppressor function, which instigates tumor 
formation (7).  
 
1.1 Rb pocket proteins family members 
 Rb is one of three proteins in the pocket protein family, made up of Rb 
(p105), p107, and p130 (8). Although Rb is frequently mutated in a wide variety 
of human cancers, Burkitt’s lymphoma, T-cell malignancies, gliomas, and some 
lung cancers have mutations of p130, whereas p107 is mutated in several 
hematologic malignancies (9-11). The common pocket domain found in each of 
the Rb family proteins is used to bind to viral oncoproteins, transcription factors, 
and other proteins. The pocket is comprised of A and B pocket domains, which 
are separated by a spacer (Figure 1). The spacer region is utilized for cyclin 
binding, whereas other proteins including E2Fs, HDACs, and viral oncoproteins 
bind in region B (12). These proteins share the LXCXE motif as well. Further, 
p107 and p130 are more closely related to each other than to Rb, though they 
can still bind to certain E2Fs, and they are also regulated by phosphorylation 
from cyclin-dependent kinases. While Rb is commonly expressed in both 
proliferating and non-proliferating cells, p107 is mainly expressed in proliferating 
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cells, and p130 is expressed in arrested cells (13). p107 being expressed in 
proliferating cells is a phenomenon which is not well understood, given that 
overexpression of p107 results in G1 arrest in some cells (14). 
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Figure 1. The family of Rb pocket proteins. The Rb protein family is comprised of 3 
members: Rb, p107, and p130. The largest region of homology between these proteins 
lies in a pocket domain (regions A and B, separated by a spacer), which is required for 
their interaction with E2Fs and many other factors. Regions within the pocket, as well as 
a domain in the carboxy terminus of Rb, have been shown to be important for E2F 
binding. Red markers represent the many regulatory phosphorylation sites that have 
been mapped in Rb, and two acetylation sites (stars) have been mapped in the carboxy 
terminus of the protein. The cyclin binding site maps to the spacer that is unique to p107 
and p130, as does a conserved domain that binds to viral oncoproteins (E1A, E7 and T 
Ag).  
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1.2  Rb interacting proteins 
 Studies have shown that Rb can bind to about 100 different proteins, 
including kinases, HDACs, HATs, histone demethylases, phosphatases and 
transcription factors—serving as a conduit between cell cycle machinery and 
promoter specific transcription initiation or repression (15, 16). These interactions 
assist Rb in the regulation of the G1 checkpoint, differentiation during 
embryogenesis and adult tissue development, regulation of apoptosis, and 
preservation of chromosomal stabililty (17). To this end, Rb can regulate the 
stability of cell cycle inhibitor p27 through an interaction with the anaphase-
promoting complex/cyclosome (APC/C). This is an important part of Rb-mediated 
arrest in G1, aside from E2F-mediated regulation (18, 19). Rb can also regulate 
the transcriptional output of additional transcription factors besides E2F. Rb can 
associate with HES1 to promote stronger binding of RUNX2 to target gene 
promoters (20). Rb also associates with Sp1, HIF1α, and MYOD transcription 
factors to modulate gene transcription (21-23). Aside from being a transcriptional 
co-factor, Rb is also an adaptor protein that can recruit a variety of co-activators 
or co-repressors to target gene promoters.  
 
1.2.1 Rb inactivation upon mitogenic and apoptotic stimulation 
 The cell division cycle comprises of essentially two distinct stages: the 
replication of DNA, collectively known as interphase, and the separation of DNA 
and other cellular organelles into two distinct daughter cells, known as mitosis. 
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The ability of cells to undergo the entire cell cycle is regulated by a variety of 
mitogens, which are factors that can initiate cell division, eventually pushing the 
cell into mitosis. Cells encounter a variety of mitogens that can initiate the cell 
cycle, including a variety of growth factors found in serum such as EGF, PDGF, 
TNF, TGF, and others (Figure 2).  Under normal conditions and during cancer, 
cyclin-dependent kinases and their binding partners, cylins, promote cell cycle 
progression (24).  Cdk1 is the most evolutionarily conserved Cdk; in the budding 
yeast Saccharomyces cerevisiae, a single Cdk equivalent to Cdk1 associates 
with multiple cyclins to regulate the cell cycle. Cdk1 is able to regulate all stages 
of the cell cycle in the absence of additional interphase Cdks (25). Although 
some cyclin/Cdk complexes have a wide array of substrates, Cdk4/6 in 
association with D-type cyclins is exclusive for the phosphorylation and 
inactivation of Rb family proteins, initiating the transition into S-phase (26, 27). 
Mitotic cyclins/Cdk complexes Cdk2/cyclin A and Cdk1/cyclin B phosphorylate 
Rb and other substrates to mediate the progression through S/G2/M phases of 
the cell cycle (28). Rb activation is reset in mitosis through the activation of 
phosphatase activity.  
 
 Rb can be phosphorylated by other kinases as well. Studies have shown 
that p38 and JNK1, both in the MAP kinase family, can affect Rb-E2F regulation 
of target gene promoters. p38 reverses Rb-mediated repression of E2F1; 
phosphorylation of Rb by p38 kinase upon Fas stimulation resulted in the 
dissociation of E2F and increased transcriptional activity during apoptosis (29). 
The inactivation of Rb by Fas was blocked by SB203580, a p38-specific inhibitor, 
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as well as a dominant-negative p38 constructs. Cdk-inhibitors as well as 
dominant-negative Cdks had no effect (30). Therefore, Fas-mediated inactivation 
of Rb during apoptosis is mediated via the p38 kinase, independent of Cdks. 
Other studies have shown that p38 directly phosphorylates Rb on Ser567, which 
is not phosphorylated during the normal cell cycle. Phosphorylation by p38, 
triggers an interaction between Rb and the human homolog of murine double 
minute 2 (Hdm2), leading to degradation of Rb, release of E2F1 and cell death, 
rather than proliferation (31).  
 
 Further highlighting a role for Rb-E2F in apoptotic signaling cascades, the 
apoptosis signal-regulating kinase ASK1 has been shown to interact with Rb 
(32). The LXCXE motif on ASK1 is required for Rb binding, which correlates with 
increased E2F1 transcriptional activity and up-regulation of the proapoptotic 
protein p73. TNFα stimulation causes Rb to dissociate from the p73 promoter, 
although conversely Rb binds to the mitogenic cdc25A promoter upon TNFα 
stimulation (32). The transcriptional induction of ASK1 also appears to be 
dependent on E2F-mediated transcription of Bim through a positive feedback 
mechanism (33). In this study, ASK1 knockdown results in reduced E2F1 
transcriptional activity, leading to decreased Bim induction after treatment with an 
HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA). Interestingly, TNFα 
can function as a mitogen, or a pro-apoptotic chemokine depending on cellular 
context. In human aortic endothelial cells, TNFα induces apoptosis, while in 
vascular smooth muscle cells (VSMCs) and aortic smooth muscle cells 
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(AoSMCs) it enhances the association of E2F1 with proliferative promoters like 
thymidylate synthase and cdc25A, along with Rb dissociation (34). Further, in 
smooth muscle cells treatment with TNFα or PDGF could stimulate the traditional 
MAPK signaling cascade in addition to stimulating the Rb-Raf-1 interaction, both 
ultimately leading to cell proliferation due to E2F recruitment at proliferative gene 
promoters (35).  Blocking the Rb-Raf-1 interaction could inhibit S-phase entry 
induced by both mitogens in this study.  
 
1.2.2 Rb inactivation by Raf-1 
 Experiments in yeast two-hybrid assays, in vitro binding assays, and 
immunoprecipitation western blot experiments revealed that Raf-1, a serine 
threonine kinase with a well characterized role in the MAP kinase pathway, could 
bind to Rb and p130, not p107 (36). Raf-1 translocates to the nucleus upon 
serum stimulation where it can bind to Rb as early as 30 minutes to 2 hours after 
mitogen stimulation (36). Raf-1 inactivates Rb and reverses Rb-mediated 
repression of E2F1 in transcriptional activity and S-phase entry assays. Further, 
the Rb-Raf-1 interaction was elevated in tumor tissue compared to normal 
adjacent tissue in eight out of 10 matched pairs, and more Raf-1 was recruited to 
proliferative promoters cdc25a and cdc6 (37). This suggests that the Rb-Raf-1 
interaction is a regulator of proliferation, and that enhanced activity through this 
signaling pathway might contribute to tumorigenesis.  
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 Further studies have aimed at examining the consequence of inhibiting the 
Rb-Raf-1 interaction. To this end, a peptide corresponding to the Rb binding 
region of Raf-1, amino acids 10-18 (ISNGFGFK with a C added to the carboxyl 
terminal end to allow coupling to the carrier molecule penetratin), was created 
(38). The inhibition of the Rb-Raf-1 interaction by the Raf-1 peptide pen-
conjugate could significantly inhibit Rb phosphorylation even up to 16 hours post 
serum stimulation (38). Importantly, B-Raf could also bind to Rb in vitro, however 
disrupting the Rb-Raf-1 interaction had no effect on the Rb-B-Raf interaction. A-
Raf had no detectable interaction with Rb. Upon more investigation, Raf-1 was 
found to specifically dissociate BRG1, a component of the SWI/SNF chromatin 
modifiers, from the promoters of E2F regulated genes—treatment with the Raf-1 
peptide pen-conjugate led to BRG1 recruitment on proliferative promoters, 
correlating with inhibited cell proliferation. Since peptides do not make good anti-
cancer therapeutics due to their propensity for degradation in vivo, we sought to 
identify a small molecule disruptor of the Rb-Raf-1 interaction. We developed Rb-
Raf-1 disruptor 251, RRD-251, which potently and selectively disrupts the Rb-
Raf-1 but not Rb-E2F, Rb-prohibitin, Rb-cyclin E, and Rb-HDAC binding (39). 
Similar to the peptide, RRD-251 inhibited Rb phosphorylation, and anchorage-
dependent and anchorage-independent growth of human cancer cells in vitro and 
in vivo. This was accompanied by inhibition of angiogenesis, proliferation, and 
phosphorylation of Rb (39). 
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1.2.3 Rb inactivation upon nicotine stimulation 
 Non-small cell lung cancer (NSCLC) comprises 80% of the total number of 
lung cancer cases and is strongly associated with tobacco use. Tobacco smoke 
contains carcinogens such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) and N’-nitrosonornicotine (NNN). These molecules form DNA adducts 
leading to mutations in vital genes like Ras, p53, and Rb (40). The carcinogen 
NNK can induce proliferation and angiogenesis through nicotinic acetylcholine 
receptor subunits (nAChRs) in a variety of cell types (41). nAChRs are 
pentameric proteins consisting of nine α subunits (α2-α10) and three β subunits 
(β2-β4) in non-neuronal cells;  ε, δ and  γ subunits are present in neuronal 
systems (41). Studies have shown a functional role for nAChRs in non-neuronal 
cells as well. Nicotine can also induce proliferation of endothelial cells (42-44), 
small cell lung carcinoma cell (45, 46) and non-small cell lung cancer cell lines 
(37).  Studies from our lab and others have demonstrated that nicotine signaling 
involves the Rb-E2F pathway and promotes cell cycle entry (Figure 2).  One 
mechanism is through the induction of the cyclin D1 promoter (47). Nicotine 
stimulation of NSCLC cell lines also leads to the binding of β-arrestin to the α7 
nAChR, which in turn activates the Src kinase-Raf-1-Rb signaling cascade (37). 
This results in dissociation of E2F1 from Rb and the induction E2F target gene 
promoters, including proliferative promoters cdc6, cdc25A, TS and survivin (37, 
48). E2F1 and p300 were recruited to these promoters when cells were treated 
with nicotine, leading to the induction of histone acetylation (48). Nicotine seems 
to be a tumor promoter in vivo, however cannot initiate tumorigenesis alone (49-
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51). Nicotine can also initiate EMT and metastasis along with proliferation (41, 
51). Overall, the inactivation of Rb by a variety of upstream signaling events can 
play a diverse role in cancer cells depending on the cell type and biological 
context.  
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Figure 2. Mitogenic and apoptotic signals stimulate the inactivation of Rb. A variety of 
signals can initiate downstream signaling cascades, including those emanating from 
nAChRs, PDGFR, TNFR, and FASR.  Rb is a major negative regulator of E2F-DP 
mediated transcription. Phosphorylation by cyclin/Cdk complexes, p38, Raf-1, and ASK1 
leads to the inactivation of Rb, releasing it from E2F-DP heterodimeric complexes, and 
allowing sequential transcription to proceed.   
Transcription of target genes 
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1.3 Downstream mediators of Rb function: the E2F family 
The E2F family comprises of 10 transcription factors sharing at least one 
conserved winged-helix DNA binding motif, while E2F7 and E2F8 have two. They 
bind the consensus sequence TTTCGCGC, as well as non-canonical sequences 
(Figure 3) (52). Since the initial discovery of E2F1 in humans, there has been an 
additional eight distinct E2F genes discovered (53-56). E2F3a and E2F3b are 
genes transcribed from different promoters, and vary only in their amino terminus 
(57, 58). In addition, although E2F3a is expressed in late G1/S phase, E2F3b is 
expressed equally in both proliferating, and quiescent cells, and is the E2F family 
member most highly associated with Rb in quiescence. E2F7a and E2F7b are 
splice variants from the same transcript, and result in a truncated carboxy 
terminus (59). E2F1-6 are recruited to target gene promoters along with 
dimerization partner proteins, TFDP1, TFDP2, and TFDP3, where this 
dimerization is mediated by the leucine zipper and marked box domains (60). 
The DP family of proteins also binds to canonical E2F binding sites, and bind to 
the C-terminus of Rb, accounting for added stringency in Rb-E2F repression 
(61). TFDP2 is similar to TFDP1, though is mainly associated with E2F4 and 
E2F5 (62-64). TFDP3 is functionally diverse from the other DP family members. 
It can inhibit transcription, prevent entry into S-phase, and abolish E2F1-
mediated apoptosis when ectopically expressed (65). 
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E2F proteins are divided into the activators (E2F1, E2F2, E2F3a) and the 
repressors (E2F3b, E2F4, E2F5, E2F6, E2F7a, E2F7b, and E2F8). This 
classification of either activators or repressors is based on the proliferative output 
when each protein is overexpressed in vitro. E2Fs1-3 can significantly induce 
gene transcription and cell proliferation, however E2F4 and E2F5 can also 
activate certain gene promoters, though to a lesser extent than E2Fs1-3 (66). 
Studies have shown that dimerization with DP proteins can enhance the 
transcriptional activity of E2F4-5; however in quiescient cells these proteins are 
usually associated with repressor complexes that contain both pocket proteins 
and corepressors. Interestingly, the classical activator E2Fs, E2F1-3a, have been 
shown to form complexes with corepressor proteins including chromatin 
modifiers like HDAC1, SUV39H1, and BRG1, suggesting that in certain contexts 
these E2Fs might also mediate transcriptional repression (67-70). Further, the 
functions of E2Fs in vivo are highly tissue specific, making classification based 
on function quite difficult (56, 71-76).  The remaining E2F family members, 
E2Fs6-8, function exclusively as repressors. E2Fs6-8 have different carboxy 
terminal features than the other E2Fs, lacking a transactivation domain and Rb 
binding domains. E2F6 can repress E2F targets when overexpressed in culture, 
and this activity is assumed to be through binding with a variety of polycomb 
group proteins (54, 77-79). E2F7 and E2F8 are the most unique structurally, 
having two DNA binding motifs, and are functionally an evolutionarily conserved 
branch of the E2F family for transcriptional repression (80, 81).  
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Figure 3. Protein structure of the E2F family.  E2F1 though E2F6 contain one DNA 
binding domain (DBD) and the leucine zipper/marked box domain region that is required 
for DP heterodimerization (LZ and MB). E2F1 through E2F5 have a transactivation 
domain (dark blue), which also contains the Rb pocket protein binding domain. E2F1-
E2F3b contain a specialized amino terminal sequence that harbors both a nuclear 
localization sequence (NLS) and region for cyclin binding. E2F4 and E2F5 are the only 
family members that contain a nuclear export sequence, and can therefore also be 
localized to the cytoplasm. The function of this localization is unknown. E2F6 cannot 
interact with Rb pocket proteins, but instead is repressed by polycomb group proteins. 
E2F7 and E2F8 have two DNA binding domains, separated by a spacer. E2F7a and 
E2F7b are splice variants, and differ only in their carboxy terminus. It is unclear whether 
corepressors or coactivators interact with E2F7 or E2F8. 
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1.4 Rb and E2Fs regulate the cell cycle 
Cells receive a multitude of stimuli, which can be either growth promoting 
or inhibitory, and arise in a cell intrinsic or cell extrinsic manner. When E2F was 
initially discovered, it was identified as an entity that was required for the early 
region 1A (E1A) transforming protein of adenovirus to transcribe the viral E2 
promoter (82-85). Nevins lab and others later discovered that E2F was targeted 
in normal cells by Rb protein (82, 83, 85). A large effort immediately followed 
identifying a role for E2F and Rb to control S-Phase entry.  
 
 To regulate the cell cycle, Rb must communicate with upstream kinases 
that impact protein binding ability of Rb, and with downstream effecter proteins, 
including the E2F family, that control gene transcription. Rb can negatively 
regulate the activation of these transcription factors by physically binding to both 
E2F and its dimerization partners (DPs) through its pocket domain and its C-
terminal domain (61, 86, 87). As mentioned previously, Rb can also recruit co-
repressors and chromatin modifiers to further repress transcription of target 
genes (88). Corepressors include HDAC1 (89, 90), BRG1/BRM (91, 92), HP1γ 
(93), SUV39H (94), Polycomb group proteins (95), DNMT1 (96), and various 
demethylases including UTX (97-99).  
 
The repressive complexes often associated with Rb and Rb family 
members are predominantly found on inactive promoters, and in the case of cell 
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cycle regulated genes these complexes are found in quiescent cells (Go). These 
complexes are often associated with the ubiquitously expressed, passive 
repressive family members, E2F4 and E2F5 (Figure 4) (66). E2F4 is the only 
E2F family member that can bind to all three Rb family members, including p130 
and p107, whereas E2F5 preferentially binds to p130. Rb is also bound, along 
with co-repressors, to E2F1-3, either at inactive target gene promoters, or as 
sequestered complexes away from target sequences (8). Upon mitogenic 
stimulation, pocket proteins are phosphorylated, and dissociated from E2F1-3 at 
target promoters, and E2F4 and E2F5 are shuttled to the cytoplasm (100, 101). 
As previously discussed, the phosphorylation of Rb is mediated by kinases 
associated with D type cyclins, mainly Cdk 4/6, followed by kinases associated 
with cyclin E, mainly Cdk 2 (102). This leads to near complete inactivation of Rb 
by mid G1 phase (103). This inactivation also eliminates the transcriptional 
repression effect of Rb, and allows E2F-DP heterodimers to recruit coactivators 
to initiate transcription of genes required for entry into S-phase (104).  Rb 
remains completely inactivated, and hyper-phosphorylated, for the remainder of 
the cell cycle. It becomes de-phosphorylated by protein phosphatases during 
mitosis (105). These events taken together are responsible for the initiation of a 
transcriptional program that can drive cells into S-phase (106). The completion of 
S-phase, and the entry into G2 is mediated by the actions of the repressor E2F 
family members, E2F6, E2F7, and E2F8 (59, 107, 108). Heteromeric and 
homomeric dimers of E2F7 and E2F8 can directly bind to the E2F1 promoter, 
and effectively repress transcription (56). The proper transition through the cell 
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cycle is thereby executed by collective cooperation between E2F family 
members. 
 
The Rb-E2F proteins are inextricably linked to the expression of various 
genes required for S-phase entry and concomitant entry into the cell cycle. This 
canon holds in human cells, where overexpression of E2F1 can drive cells into S-
phase (109), Drosophila, where dE2F1 overexpression induces S-phase (110, 
111), and Arabidopsis, where differentiated and non-dividing leaf cells can re-
enter S-phase upon AtE2F-a  overexpression with AtDP-a (112). Further, 
activator E2Fs have been shown to overcome anti-proliferative signals, from 
TGFβ (70), in addition to their transformation capabilities when overexpressed in 
primary cells (109, 113-116).  Of the genes identified that are rate limiting for cell 
cycle entry, cyclin E and cyclin A have been identified as true targets of E2F1-3 
(117). Other targets have more specificity to which E2F family member is the 
main regulator depending on cell type, for example cdc6, cdc25a, p107, and c-
myb are all strongly regulated by E2F1 and E2F3 in rat fibroblasts (117). 
Dihydrofolate reductase, Thymidylate synthase, cyclin D3 and Thymidine kinase, 
enzymes required for nucleotide synthesis, are also regulated by multiple E2F 
family members (64, 117, 118). Genes involved in G2/M are also E2F targets, 
including cyclin B1, cyclin A2, cdc20, DBC2 (119) Bub1 mitotic checkpoint 
protein kinase, KRP1/2 mitotic motor proteins, and AIM1, a chromosome 
segregation kinase (120, 121). DNA replication genes including MCM2-7, 
multiple subunits of DNA polymerase, FEN1, PCNA, Replication protein A2, and 
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Topoisomerase 2α were also identified using microarray in various systems (120, 
122, 123).  
 
The expression of each E2F family member is crucial for the proper 
execution of the mammalian cell cycle, and this is also dependent on the 
association of these proteins with specific Rb family members. Several groups 
have sought to find ways to inhibit the inactivation of Rb, keeping it active as an 
E2F-repressor, and therefore inhibiting uncontrolled cell proliferation. This may 
be a possible therapeutic option for proliferative diseases.  
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Figure 4.  The contribution of E2Fs to cell cycle progression. In quiescient cells (G0), 
E2F4 and E2F5 associate with pocket proteins and other corepressors, preventing entry 
into the cell cycle. Upon mitogenic stimulation, Rb is phosphorylated, mainly by 
cyclin/Cdk complexes, and inactivated and the E2F repressor proteins are freed from 
E2F binding sites; E2F1-E2F3 take the place of E2F4-5. The recruitment of E2F1-3 
allows for transcription of genes required for S-Phase entry and DNA replication (dashed 
line). Upon completion of S-phase, E2F proliferative promoters are inhibited by E2F6-8 
independent of pocket protein binding.  During late G2/M phase, Rb is dephosphorylated 
by protein phosphatases, enabling active Rb to again repress E2F-mediated 
transcription until it is further required.  
  
21 
 
1.5 Additional E2F target genes 
With the development of precise high throughput gene profiling arrays and 
chromatin immunoprecipitation arrays (ChIP on chip), genes involved in 
apoptosis, signal transduction, transcriptional control, and membrane biology 
were identified as potential E2F targets (52, 120-129). Though E2Fs were 
originally assumed to be exclusive cell cycle regulators, these studies where 
among the first to allude to the possibility of E2Fs functioning in different 
biological settings and performing tasks unrelated to proliferation. This section 
aims to discuss the E2F target genes which play roles outside of proliferation.  
 
1.5.1 E2Fs regulate apoptosis 
The surprising observation that E2F1 knockout mice develop normally 
only to develop tumors of multiple locations as they age, including reproductive 
tract sarcoma, lung tumors, lymphoma and other tumor types along with tissue 
atrophy and glandular dysplasia was among initial evidence suggesting that 
E2F1 was a tumor suppressor gene, in addition to an oncogene (71). Taken with 
the observation that thymocytes of E2F1 null animals were hyperproliferative and 
had defects in apoptosis, it was established that, at least in vivo, E2F1 was a key 
mediator of apoptosis (71, 73). There are conflicting reports as to the degree of 
specificity for apoptotic inducers between E2F family members. Although it 
originally seemed that E2F1 was the sole inducer of apoptosis, (64, 130-132), 
E2F2 and E2F3 could also push cells towards apoptosis, though to a much 
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lesser extent than E2F1 (64, 117, 133, 134). Later studies demonstrated that 
E2F-mediated apoptosis was indeed through caspases 3, -7, -8, and -9 and 
could be through p53-dependent mechanisms as well (135-138). p53-dependent 
apoptosis is induced through p19ARF (139, 140) in mouse and human models, 
and therefore inhibits MDM2-mediated degradation of p53 protein (141, 142).  In 
addition to caspase upregulation, E2F1 transcriptionally targets pro-apoptotic 
genes, including p73 (143), Apaf-1 (144), Bid (145), SIVA (146) and BH3-only 
genes such as PUMA, Noxa, Bim, and Hrk/DP5 (147). E2F1 up-regulates the 
expression of genes that are pro-apoptotic cofactors of p53, such as ASPP1 
(apoptosis stimulating protein of p53) and ASPP2, thereby biasing p53 to activate 
pro-apoptotic genes and induce apoptosis (148-150). How cells determine 
whether to turn on pro-apoptotic genes or proliferative genes is still not clear, 
though JAB1 has been shown to only mediate the induction of pro-apoptotic E2F 
target genes (151). In addition to activation of pro-apoptotic proteins, E2F1 can 
also repress anti-apoptotic genes like MCL-1 (152).  
 
HDAC inhibitors such as suberoylanilide hydroxamic acid (SAHA) and 
trichostatin A (TSA) have been shown to promote E2F1-mediated apoptosis 
through the induction of pro-apoptotic Bcl2 family member Bim through p53 and 
p73-independent mechanisms (153). As mentioned previously, p38 has been 
shown to phosphorylate Rb in response to stress and death receptor signaling in 
multiple cell types, such as endothelial cells, cerebellar neurons, Jurkat 
lymphocytic cells, colon cancer cells, and melanoma cells (29, 30, 154-157).  
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Interesting studies from Talianidis lab have shown that Set9 methylates 
E2F1 at lysine-185, which prevents E2F1 accumulation and activation of p73 
(158). This methyl mark is removed by LSD1, which is required for E2F1 
stabilization and apoptotic function. Overall, the induction of apoptosis by 
deregulated E2F1 is by now well established and the studies discussed above 
provide a number of components that mediate apoptotic activity. However, 
keeping in mind the pivotal role of the E2F family in regulating cell proliferation, it 
is imperative to better understand the mechanism determining whether the final 
outcome of E2F activity will be survival or death (159). 
 
1.5.2 E2Fs regulate autophagy 
The role of E2F-induced apoptosis in both normal development and 
disease is well-studied; other forms of cell death induced by E2F1 are less clear. 
Unlike the caspase cascades that mediate apoptosis, autophagy is an 
evolutionarily conserved vesicular-trafficking process that mediates the 
degradation of cytosolic proteins and organelles (160). Initial studies in Rb-null 
hepatocytes showed autophagic traits, and E2F regulated BH3-only protein 
BNip3 was required for hypoxia-induced autophagy (161). Also, activation of 
E2F1 upregulates LC3, ATG1, ATG5 and DRAM, and enhances autophagy. In 
addition reducing endogenous E2F1 expression inhibits DNA-damage-induced 
autophagy (162, 163). Beclin 1, an essential autophagic gene, depends on E2F 
transactivation of the promoter, and upregulation of Beclin 1 by 14-3-3τ also 
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requires E2F1 (164). In the same study, depletion of E2F1 or 14-3-3τ inhibits 
autophagy. There is also evidence that in certain settings, Rb can induce 
autophagic-vacuole formation by inhibiting E2F function, and overexpression of 
E2F1 will bypass Rb-mediated autophagy, directing a cell for apoptosis (165). In 
fact, it seems that E2F transcriptional programs, which drive apoptosis and 
autophagy, may have overlapping functions. For example, the nutrient energy 
sensor AMP kinase α 2 (AMPKα2), which is an inducer of autophagy, is also a 
pro-apoptotic E2F1 target gene (161). An open question is whether E2F-induced 
autophagy results in cell death or cell survival—though like other E2F-mediated 
biological processes, cell type, stimulus, and temporal activation most likely 
direct the outcome.  
 
1.6 Rb and E2F knockout mouse models 
The generation of the Rb knockout mouse was the first successful mouse 
model with targeted deletion of a tumor suppressor gene (166-168). The most 
enigmatic finding in these animals is that they are not predisposed to 
retinoblastoma, which is observed in the human situation, however some display 
pituitary tumors. The Rb null mouse is embryonic lethal, exhibiting neuronal cell 
death and defective erythropoiesis. These developmental defects appear to be 
attributed to aberrant E2F activity; combined deletion with either E2F1 or E2F3a 
animals can robustly suppress the Rb-mutant phenotype, and extend viability 
(68, 169). Studies on E2F knockout mice have provided some surprising 
information about the function of E2Fs in vivo. As mentioned previously, E2F1 
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knockout animals develop testicular atrophy, and tumors in several organs 
including sarcomas, lung tumors, and lymphomas (71). They also develop 
increased number of thymocytes, due to defects in apoptosis (73). E2F2-/- 
animals die early from autoimmune disease accompanied by widespread 
inflammatory infiltrates, glomerular immunocomplex deposition, and anti-nuclear 
antibodies (170). E2F1-/-;E2F2-/- animals develop insulin-deficient diabetes and 
exocrine pancreatic dysfunction, dysplasia, and a reduction in the number and 
size of acini and islets, being replaced by ductal structures and adipose tissue 
(171, 172). Surprisingly, mutant pancreatic cells exhibit increased rates of DNA 
replication and apoptosis, ultimately resulting in pancreatic atrophy (171). E2F3-
deficient mice arise at one-quarter of the expected frequency, demonstrating that 
E2F3 is important for normal development, and mice which do survive are 
severely runted, primarily from insufficient proliferative gene transcripts including 
B-myb, cyclin A, cdc2, cdc6, and DHFR (173-175). Further, elegant knock-in 
studies demonstrate that E2F3a1ki or E2F3a3bki could suppress these postnatal 
phenotypes seen from E2F3a knockout (175).  Dissecting the E2F3a versus 
E2F3b isoform functions, only loss of E2F3a (176), and not E2F3b gave a slight 
decrease in white adipose tissue. However E2F1-/-;E2F3a-/- double mutant 
animals die around one month with under-developed sex organs, reduced 
pancreatic exocrine cells and other developmental defects (175, 176). E2F1-/-
;E2F3b-/-  animals are viable and fertile, demonstrating the crucial role of the 
E2F3a isoform (175). Triple knockout mice, E2F1-/-;E2F2-/-;E2F3-/-, are embryonic 
lethal, with no clear disturbances to proliferation (177, 178). Mice lacking E2F4 
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surprisingly show no abnormalities in cell proliferation or cell cycle arrest. 
However, E2F4 is essential for normal development—mice lacking E2F4 have 
several developmental defects including impaired erythroid proliferation, 
hematopoietic lineages maturation defects and craniofacial abnormalities, 
making animals more susceptible to opportunistic infections (179-181). E2F5 null 
mice develop normally with no defects in cell proliferation, however newborn 
mice develop non-obstructive hydrocephalus, suggesting excessive 
cerebrospinal fluid (CSF) production by the choroid plexus (75). E2F6-/- mice 
have a normal lifespan, similar phenotype to PcG null mice (76). Further, E2F6 is 
essential for the long-term somatic silencing of certain male-germ-cell-specific 
genes, but it is dispensable for cell cycle regulation (76). E2F7 and E2F8 null 
mice have no observed phenotype, though the combined knockout, E2F7-/-; 
E2F8-/-, animals are embryonic lethal with widespread apoptosis, vascular 
dilation and hemorrhage. One can conclude that, at least in mice, the 
“repressive” arm of the E2F family is crucial for development but are dispensable 
for tumor formation (56).  
 
1.7 Alterations of the Rb-E2F pathway in cancer 
 The oncogenic capacity of E2F was highlighted when it was shown to 
transform cells when overexpressed with other oncogenes such as RAS and c-
MYC (115, 182). Although mutations in Rb have been found in a variety of 
human cancers, mutations in E2F family members remain fewer than Rb 
mutations (66). Being a classic tumor suppressor gene, both copies of the Rb 
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gene locus are mutated in both sporadic and inherited retinoblastoma. The 
retinoblastoma gene often undergoes point mutations and partial gene deletions, 
resulting in an mRNA species and a truncated protein product (183). Mutations in 
the Rb gene have been identified in various tumor types, including osteosarcoma 
(90%), breast cancer (20%), small-cell lung cancer(>90%), non-small cell lung 
cancer (30%), prostate cancer (20%), melanoma (rare, but inherited mutation 
predisposes to melanoma), bladder cancer (20-50%), CML (20%), and gliomas 
(15-30%) (184-194). Although not by mutation, human papillomavirus (HPV) is 
thought to initiate cervical carcinoma and squamous cell carcinoma of the head 
and neck in part by inactivating Rb with the E7 protein (195). Further, the Rb 
pathway is mutated in most cancers, either through targeting upstream regulators 
such as cyclin D or p16, or downstream effectors such as E2F proteins 
themselves. Amplification of the cyclin D1 gene is observed in human laryngeal 
squamous cell carcinomas, breast cancer, anal and esophageal squamous cell 
carcinomas, mantle cell lymphomas, and some lung cancers (196-200). In all 
cases over-amplification of the cyclin D or cdk4 kinase can lead to Rb 
phosphorylation, inactivation, and thereby release its role as an active tumor 
suppressor. Negative regulators of cyclin-Cdk activity are also frequently mutated 
in cancer, such as p16, p21, or p27 (201-204).  
 
In human cancers, there is also sufficient evidence of aberrant E2F 
expression in divergent tumor types, hinting at the important role for E2F activity 
in various organs (66, 205). In fact there are reports linking E2F1 or E2F3 locus 
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amplification to hepatocellular carcinoma (206-209), bladder cancer (210-213), 
retinoblastoma (214, 215), and liposarcoma (216, 217). In the case of bladder 
cancer, this amplification imparts cells with rapid growth and more invasive 
capacity (218). Similarly, malignant melanoma has increased copy number of 
E2F1 (219). Overexpression of E2F1-3 has been observed in glioblastoma (220), 
lung (221-225), ovarian (226, 227), breast (228, 229), gastric (230-232), and 
colon cancer (233, 234). Chromosomal deletions of E2F1, E2F2, and E2F3 
genes have also been detected in several cancers including neuroblastoma (235, 
236), thyroid (235), and pancreatic cancer (237, 238). Despite E2F4 and E2F5 
being part of the repressive arm of the E2F family, there are few mutations, 
deletions, or silencing events of these genes identified in human cancer. One 
study highlights that the E2F5 gene is amplified along with MOS and MYC in 
breast cancer, and minimal common region 8q21.3-8q23 in osteosarcoma (239, 
240) (241). There is also increased expression of E2F4-8 in several cancers, 
including breast (241, 242), colon (243, 244), ovarian (226, 227, 245), and skin 
(246).  Whether these mutations are oncogenic remains unclear. 
 
1.8 Rb and E2Fs in angiogenesis and tumor progression 
Angiogenesis, the formation of new blood vessels from the pre-existing 
vasculature, is a critical step in normal embryonic development, wound healing, 
inflammation, and a precursor for tumor progression. By extending the 
vasculature within a tumor, adequate supply of oxygen and metabolites enable 
the mass to grow. In early stages of angiogenesis, endothelial cells and tumor 
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cells secrete proangiogenic factors such as vascular endothelial growth factor, 
VEGF, and basic fibroblast growth factor (bFGF) and interleukin-8 (IL-8), which 
stimulate endothelial cell proliferation, migration, and differentiation into the tumor 
bed (247-249). pRb is necessary for cyclin A1 to induce autocrine expression of 
VEGF (250),  and mice defective of p130 had impaired new vessel growth, and 
therefore less tumor xenograft growth (251). Several genes that are responsive 
to VEGF and required for angiogenesis are regulated by E2Fs; these direct E2F 
target genes include human metallothionein 1G (hMT1G) (252), VEGF receptor 1 
(FLT-1), VEGF receptor 2 (KDR), angiopoieten 2 (ANGPT2) (253) and platelet-
derived growth factor receptor α (PDGFR-α). Thrombospondin-1 (TSP-1), an 
anti-angiogenic glycoprotein, is also an E2F1 target gene (254). E2F1, E2F2 and 
E2F3 can activate the fibroblast growth factor receptor 2 (FGFR-2) promoter, 
contributing to malignancy (255, 256). 
 
Several studies have provided initial evidence that Rb-E2F pathway may 
regulate tumor progression. Reconstitution of pRb in various cancer cell lines 
suppresses tumorigenicity in nude mice and confers less tumor cell invasion in 
vitro (257). Overexpression of Ad-E2F1 in NIH3T3 fibroblasts resulted in a down-
regulation of several genes involved in proteolysis (122) whereas vascular 
endothelial growth factor B (VEGF-B), matrix metalloproteinase 16 (MMP16), and 
fibroblast growth factor 2 (FGF-2) are induced through direct and indirect 
mechanisms upon E2F activation in another study (258). In addition, high levels 
of E2F1 were found in lung metastasis of colon cancer and associated with high 
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levels of TS (259). E2F overexpression in head and neck carcinoma cell lines 
also conferred more invasive properties in vitro; there was also an additive effect 
on proliferation (260). There is evidence that E2F activity is required for integrin 
α6β4-mediated invasion of breast cancer cells, and that α6 integrin is highly 
expressed in metastatic 4T-1 cell lines leading to higher expression of E2F target 
genes (261, 262). Taken together, these studies suggest a positive-feedback 
loop, and add to the complexity of E2F-mediated tumor progression. 
 
2. Regulation of tumor progression 
 Cancer was originally conceived to be little more than the sustained 
proliferation of a cell population. After decades of research, the nature and 
diversity of cancer is better characterized; the characteristics most frequently 
seen in tumors had been placed into six hallmarks: angiogenic capability, 
replicative immortality, invasive and metastatic capability, evasion of growth 
suppression, resistance to cell death, and sustainable proliferative signaling 
(263).  In addition to the original six hallmarks, the ability to deregulate cellular 
energetics (presumably due to genomic instability and mutation) and avoid 
immune destruction (partially due to inflammation in the tumor microenvironment) 
was added to the list. (264).  It is therefore intriguing which proteins and 
pathways can connect these hallmarks regulating early stage events to late stage 
events—we hypothesize that the Rb-E2F pathway might be a major link between 
these events (Figure 5). This section aims to discuss the ominous complexity of 
the progression of cancer.  
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Figure 5.  The Rb-E2F pathway regulates many hallmarks of cancer.  The list of E2F 
target genes keeps growing each year. Connecting E2F to cell cycle regulation, genes 
that are required for S-phase entry like cdc6, cdc25a, and TS among others are direct 
E2F targets. Apoptotic E2F target genes include Bok, Caspase-3, Caspase-7, PUMA, 
and others. Several angiogenesis genes are regulated by E2Fs, including FGF, FGFR-2, 
FLT-1, KDR, angiopoiten-2, and VEGF.  The MCM genes MCM2-7 are required for DNA 
replication, and regulated by the Rb-E2F pathway. Data suggests that genes required for 
autophagic vessel formation including LC3, ATG1, ATG5, and DRAM are regulated by 
E2F, while DNA repair genes like RAD51, and BRCA1 are also E2F-regulated.  Rb and 
related pocket proteins tightly control the regulation of differentiation. Several studies 
highlight a role for the Rb-E2F pathway in metastasis as well, linking the Rb-E2F 
pathway to most processes in cancer.  
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2.1 Metastasis as a multistage process 
 For a tumor to progress from a primary neoplasia to metastases, multiple 
reprogramming events occur to promote the process (265-267).  Further adding 
to this complexity, primary tumors will often colonize specific organs, have 
different rates at which metastasis emerges, and respond differently to various 
therapeutics (268).   However, the simplified view is that metastasis is an orderly 
process of five steps: local invasion into stroma, intravasation into blood vessels, 
survival in circulation, extravasation at the distant site, and finally colonization at 
the distant site (266, 268, 269).   
 
As previously described, there are various mutations that occur depending 
on the site of the primary tumor; these are the initiating mutations, and can 
include the induction of oncogenes such as KRAS, PI3K, EGFR and others in 
NSCLC (270), B-RAF in melanoma (271), or HER-2 in breast cancer (272). 
Tumors can arise from the silencing of genes as well, including well-known 
examples such as p53 in many tumor types (273), or BRCA1 and BRCA2 in 
breast and ovarian cancer (274).   These mutations can be a requirement for 
metastasized cells as well, a theory supported by studies showing that in mouse 
models of breast cancer Erbb2-dependent breast tumors and metastatic lesions 
shrink when treated with ERBB2 antibody therapy (275). Conversely, in other 
models of cancer with tumor formation being driven by oncogene induction, 
  
33 
metastasis is not always inevitable (276). Further, some patients have detectable 
cancer cells in circulation but never develop metastasis (277).  
 
2.2 Epithelial to mesenchymal transition (EMT) and mesenchymal to 
epithelial transition (MET) 
The observation that primary carcinomas could progress to higher 
pathological stages, which had localized invasion and eventual metastasis, was 
coupled to the observation that epithelial cells could change shape and free 
themselves from other cells. This event was later molecularly characterized as 
the loss of E-cadherin either by mutation or dowregulation of the transcript (278) 
(279)—one of many molecular changes in the epithelial to mesenchymal 
transition (EMT).  Signals emanating from the microenvironment such as HGF, 
EGF, PDGF and TGF-β appear to turn on oncofetal transcription factors including 
Goosecoid, FOXC2, Snail, Slug, Twist and Zeb1/2, which are known to mediate 
the EMT process during embryogenesis, fibrosis, and cancer (at least in vitro and 
in animal models)(280-284).  Further, these transcription factors have been 
shown to cause metastasis when ectopically expressed (285-287), presumably 
through the direct trans-binding to the E-cadherin promoter (288, 289). When this 
key suppressor of motility is repressed, cells are free to mobilize and invade 
surrounding tissues. In addition, cells that lose epithelial markers such as E-
cadherin will concomitantly gain mesenchymal markers such as vimentin, 
fibronectin, desmin, FSP1, α-SMA and N-cadherin (287). These molecular 
markers correlate with a spindle-shaped, or fibroblast-like morphology, making 
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cells more motile with higher matrix-degrading enzyme levels as well. 
Interestingly, cells at the tumor leading edge have been shown to undergo EMT 
at higher rates than cells at the core of a solid tumor (290) suggesting that EMT 
could be a result of signaling from cell extrinsic factors in the tumor 
microenvironment. This interaction is likely a part of the crosstalk between 
stromal cells and cancer cells (291) and leads to a small sub-population of tumor 
cells that can intravasate, survive in circulation, and colonize. In order for cells 
that have undergone EMT to colonize the secondary site, they must be able to 
revert back to an epithelial state. This is accompanied by genetic changes 
pushing cells to a more epithelial state, or an MET, and is likely also prompted by 
differing signals in the new microenvironment (292). Importantly, cell-intrinsic 
signaling pathways must also be intact to transduce these processes, utilizing 
proteins such as ERK, MAPK, PI3K, AKT, SMADs, and Ras (293). Although this 
model for cancer cell dissemination in the context of EMT has been shown for 
many cell lines in vitro and in animal models, more experimental validation is 
required to determine the global nature of the process, and whether this occurs in 
human tumors.  
 
2.3 Mechanisms of invasion 
 The invasion process demonstrated by cancer cells to breach the 
basement membrane and initiate the metastatic process appears to be mediated 
through both proteolytic degradation of surrounding tissue and methods of 
physically moving the tumor cells through the surrounding tissue (267, 294). The 
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surrounding tissue, or extra-cellular matrix (ECM) is comprised of a 
macromolecular network of proteins, glycoproteins, and proteoglycans that aim to 
maintain the tissue architecture (295, 296). The precise biology of the ECM that 
confronts invading tumor cells can vary between the 2-D sheet like conformation, 
and the 3-D fibrillar meshwork of the interstitial compartment (297). In either 
case, the ECM composition impeding the outgrowth of cells is a significant 
physical barrier, and therefore cancer cells must utilize various stratagems for 
trafficking through the matrix.  
 
 The initial barrier in epithelial cancers is the basement membrane. It is 
comprised of over 50 components, mostly interwoven laminin and type IV 
collagen (298, 299) that contain various degrees of covalent crosslinking 
including disulfide and lysyl oxide–derived aldimine bridges. Studies have 
demonstrated that this network generates pores of approximately 50 nm, and 
that normal and cancer cells alike are unable to migrate through pores less than 
2.0 µM in diameter (300-302). As described earlier, in order to remodel the 
basement membrane to allow for cancer cell migration, cells can reactivate 
programs used in embryonic development, the developmental EMT (287, 303). 
Conversely, however, it is possible that the basement membrane remodeling is 
the event which activates EMT in cancer cells—suggesting a paracrine loop 
between cells and their surrounding extra-cellular barriers (304).  
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Proteolytic machinery remains the crux of the process to effectively 
remove part of the basement membrane (305-308). This has been demonstrated 
in vivo as well, where type IV collagen networks are substantially degraded (305, 
308-310). Although there are hundreds of proteases in the human degradome, 
numerous studies have highlighted a role for the matrix metalloproteinase family 
in various aspects of angiogenesis, EMT, resistance to apoptosis, and 
degradation of the BM and ECM. It is difficult to dissect an unambiguous role for 
each protease given their diverse substrates: the BM itself, chemokines and 
growth factors in the matrix (being able to both activate or inactivate), cell surface 
receptors, and adhesion molecules (311).  Once passing through the BM, cells 
no longer maintain a differentiated state, and they continue to an environment of 
primarily type I collagen, or the 3-D ECM (294, 297, 311-314). Once cells are in 
the type I collagen networks, they utilize integrins and other cell surface markers 
to further promote EMT, migration, and degradation phenotypes, either moving 
as a single cell or a cell mass (315, 316). The goal of proteolytic systems is to 
provide cells a large enough diameter to pass through (317, 318). However, 
conflicting and complimentary reports have also suggested that protease-
independent transmigratory schemes are used as a means to infiltrate type I 
collagen barriers (314, 319-322), including following other leading cells through 
the ECM (323, 324).   It is logical that cells may utilize a combination of these 
methods in order to circumvent physical constraints and eventually intravasate 
into the vasculature.  
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2.4 Circulating tumor cells 
  Once cells have successfully navigated through the ECM and enter the 
tumor vasculature, they are once again faced with an entirely new set of 
challenges in the bloodstream. The bloodstream is an inhospitable environment 
for cancer cells; they have to undergo velocity-induced shear forces, survive 
without a substratum, and ward off any attempts at elimination by immune cells 
(267, 325). The tumor cells will often times suffer collisions with host cells, such 
as leukocytes and endothelial cells that line vessels.  Further, cells favor growing 
on a surface, and without this attachment cells face the risk of cell death—also 
known as anoikis (326). Only the circulating tumor cells (CTCs) which are 
resistant to anoikis, can overcome shear forces, immunosurveillance, and then 
adhere to the vascular endothelium of organs will have a chance to survive, and 
colonize at their distant site. Only a minute fraction of CTCs survive, whereas 
most die or remain dormant for months, or even years, depending on the tumor 
type (268, 327). Beyond survival, cells also need to end their journey either by 
binding to coagulation factors within the vessel, or by mechanical trapping 
(physical occlusion) in the capillary bed. The coagulation factors are variable 
depending on the location the tumor cell arrests, including E-selectin, P-Selectin, 
I-CAM1, V-CAM1 and others on the endothelial cells, and linking to CD44, CEA, 
PODXL, and integrins on the tumor cell surface (325). Other studies have shown 
that tumor cells can metastasize early, and then complete their proliferation 
inside the vasculature before adhesion (328).  Tumor cells of epithelial origin are 
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approximately 10 µM in size or greater, and small vessels or capillaries are less 
than 10 µM (325, 329). To add to the variability of factors that contribute to 
metastasis complexity, capillary beds can express different factors. For example 
metadherin is a protein that can home breast cancer cells to the lung rather than 
the skin, kidney, or other organs. Targeting metadherin with antibodies or siRNA 
could reduce experimental metastases, demonstrating that molecular markers 
could be viable anti-metastatic therapeutics (330). 
 
2.5 Metastatic colonization 
 The final step of metastasis is the infiltration and colonization of distant 
organs by CTCs. This requires the passage through the capillary walls and 
survival in the new parenchyma (268). The genes required for this colonization 
could already be expressed, or deregulated in the primary tumor; however once 
metastasized, these alterations might serve a different function at the new locale.  
Further, the composition and structure of certain organs may be more pervasive 
to metastatic infiltration than other organs, which could possibly account for the 
organ site-specific metastasis seen in humans (268). The most typical sites for 
metastatic relapse of solid tumors are the bone, lungs, brain, liver, and lymph 
nodes (Figure 6) (268). The molecular characterizations of these different 
microenvironments from the major sites demonstrate some similarities to the 
primary location. It also shows distinct differences, calling a demand for site-
directed therapeutic strategies. There is growing evidence observed in mouse 
xenograft studies that the microenvironment where the CTCs “home” to plays a 
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large role in metastastic colonization, including the presence of myeloid derived 
suppressor cells, endothelial, and mesenchymal lineage (331-333). Stephen 
Paget when describing the tumor cells and their environment as the “seed” and 
the “soil” initially predicted these observations in 1889 (334).   
 
2.5.1 Metastasis to bone 
 One of the most well characterized sites for metastasis, the bone, is a 
common site for breast cancer, multiple myeloma, and prostate cancer 
metastasis (266-268, 335). This type of metastasis is often paired with 
osteoblastic (bone forming) and osteoclastic (bone degrading) activities which is 
prompted either by chemokines secretion from the tumor cells or 
microenvironment (335). The activation of osteoblasts can be accomplished by 
activation of transcription factor Runx-2 and osterix, usually by chemical signals 
such as IGF-1R, FGFRs and endothelins (336). The osteoclastic lesions develop 
as part of the ‘vicious cycle’ where tumor cells secrete parathyroid hormone-
related protein (PTHrP), which stimulates osteoblasts to produce RANK ligand 
(RANKL) and osteoprotegerin (OPG). After these osteoclasts are activated, the 
degraded bone matrix can release embedded growth factors like IGFs and 
TGFβ, which can then turn tumor cells more virulent. In addition, interleukin-11, 
MMP-1, chemokine receptor CXCR-4, and the connective tissue growth factor, 
CTGF, which can be secreted by other cells in the bone microenvironment can 
induce PTHrP-independent osteoclastic activity and aid bone metastasis (337).  
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To this end, a monoclonal antibody against PTHrP is in preclinical development 
(338, 339).  
 
Recent studies have characterized a bone metastasis dormancy model 
that shows aberrant expression of vascular cell adhesion molecule 1 (VCAM-1), 
in part dependent on the activity of the NF-κB pathway, promotes the transition 
from micrometastasis to overt metastasis (340). Further, antibodies against 
VCAM-1 and integrin α4 effectively inhibited bone metastasis progression and 
preserved bone structure (340). A disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTS1) and matrix metalloproteinase-1 (MMP-1) in 
tumor cells can also orchestrate a paracrine signaling cascade to modulate the 
bone microenvironment in favor of osteoclastogenesis and bone metastasis 
(341). Correspondingly, MMP1 and ADAMTS1 expression is associated with 
increased risk of bone metastasis in breast cancer patients (341). Proteolytic 
release of membrane-bound epidermal growth factor (EGF)-like growth factors, 
including Amphiregulin (AREG), heparin-binding EGF (HB-EGF), and 
transforming growth factor alpha (TGFα) from tumor cells suppressed the 
expression of osteoprotegerin (OPG) in osteoblasts. Another oncogene important 
for bone metastasis of breast cancer, Src, is dispensable for homing to the bones 
or lungs but is critical for the survival and outgrowth of these cells in the bone 
marrow (342).  
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Figure 6. Common sites for metastases. The formation of bone metastasis is a common 
event in many types of solid tumors, particularly breast and lung cancer. Metastasis to 
the liver is primarily through the large portal-vein system, and seeding the blood-rich 
organ is also particularly common for pancreatic and colorectal cancers. Metastasis to 
the brain can occur after months or years of cancer dormancy, and is frequently 
observed in lung, breast, and melanoma patients. The lungs are also a prime location for 
tumor cells to become trapped by occlusion in the small lung capillaries.  
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2.5.2 Metastasis to lung 
In animal models, the tail vein metastasis model is one of the most utilized 
methods to study late stage events in metastasis. Another animal model of 
metastasis to the lungs is the breast cancer orthotopic model—where cells are 
xenografted into the mammary fat pad of mice, and over time cells 
spontaneously metastasize to the lungs (343). Along with the lung orthotopic 
model, where cells are directly implanted into the lung, there are several assays 
used to measure metastasis in mice. Because of these experimental stratagies, 
studies looking for potential molecular pathways contributing to lung metastasis 
are numerous. An elegant study from Massagué lab demonstrated that human 
breast cancer cell lines that metastasized to the lung shared a gene signature 
different from those cells that could metastasize to the bone, although a single 
gene could not recapitulate the phenotype  (343). In this study a 54-gene 
signature was established, only cells overexpressing ID1 alone were modestly 
more active at forming lung metastases than cells infected with vector controls 
(343). Other genes tested for functional validation included the epidermal-growth-
factor family member epiregulin (344), the chemokine GRO1/CXCL1, the matrix 
metalloproteinases MMP1 and MMP2 (gelatinase A), the cell adhesion molecule 
SPARC, the interleukin-13 decoy receptor IL13Rα2, the cell adhesion receptor 
VCAM1, and the prostaglandin-endoperoxide synthase PTGS2/COX2. The 
expression of ID1, CXCL1, COX2, EREG and MMP1 increased with lung 
metastatic ability (343). A follow-up study showed ID1 and its closely related 
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family member ID3 were required for tumor initiating functions, both in the 
context of primary tumor formation and during metastatic colonization of the lung 
microenvironment (345). Other groups have also demonstrated a propensity for 
metastasis when ID1 is upregulated or overexpressed (346-351). 
 
Numerous other pathways have also been implicated in lung cancer 
metastasis, including cell survival, resistance to cell death, inflammatory 
pathways and antiapoptotic pathways—utilizing proteins such as ezrin, TGFβ, 
Bcl-2, Bcl-xL, DAP, IAP, and NF-κB (352-361). Based on clinical, functional, and 
molecular evidence, it seems that TGF-β in the breast tumor microenvironment 
also primes cancer cells for metastasis to the lungs (362). Central to this process 
is the induction of angiopoietin-like 4 (ANGPTL4) by TGFβ—enhancing their 
subsequent retention in the lungs through disruption of vascular endothelial cell-
cell junctions, which increases the permeability of lung capillaries (362). In 
addition, the expression of tenascin C (TNC), an extracellular matrix protein of 
stem cell niches, was shown to be associated with survival and outgrowth of lung 
micrometastases (363). TNC enhanced the expression of mushashi homolog 1 
(MSI1) and leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5)—
MSI1 is a positive regulator of NOTCH signaling, whereas LGR5 is a target gene 
of the WNT pathway (363). Importantly, TNC protected MSI1-dependent NOTCH 
signaling from inhibition by signal transducer and activator of transcription 5 
(STAT5), and selectively enhanced the expression of LGR5.  
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2.5.3 Metastasis to brain 
 Brain metastasis affects an estimated 10% of cancer patients with 
disseminated disease (364, 365). Even small lesions can cause neurological 
disability, and the median survival time of patients with brain metastasis is short. 
Brain metastasis is the most common in people with lung and breast cancer, and 
also observed in melanoma (366). Metastasis from lung adenocarcinomas 
develops within months of diagnosis and affects several organs besides the brain 
(367). However the display of a brain metastasis can occur years, and even 
decades after the removal of a small primary malignancy, suggesting that the 
phenotype required to infiltrate the brain microenvironment is far more advanced 
than the requirements of either the lung or bone microenvironment (268, 368, 
369).  This difficulty to colonize the brain could be partially due to the unique 
nature of the blood-brain barrier, which is connected by tight junctions, filled with 
efflux pumps and surrounded by a basement membrane coated in astrocytes and 
pericytes (267, 268). Once within the brain, tumor cells are faced with astrocytes 
and glial cells which can stimulate the production of cytokines, chemokines, and 
growth factors. Further, the catecholamine neurotransmitters norepinephrine, 
dopamine, histamine, angiotensin, and substance P have all been reported to 
induce tumor cell motility  (370). With the same method used to study breast 
cancer metastasis to the bone (337) and lung (343), studies show that breast 
cancer infiltration of the brain requires general mediators of extravasation, 
complemented by specific enhancers of cell passage through the blood-brain 
barrier (371). Cells from patients with advanced disease were isolated that 
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preferentially infiltrate the brain. Gene expression analysis of these cells and of 
clinical samples, coupled with functional analysis, identified cyclooxygenase 
COX2, the EGFR ligand HBEGF, and the α2, 6-sialyltransferase ST6GALNAC5 
as mediators of cancer cell passage through the blood–brain barrier (371). 
Interestingly the expression of ST6GALNAC5, which is normally only expressed 
in the brain, and therefore when expressed in breast cancer cells enhances their 
adhesion to brain endothelial cells and their passage through the blood–brain 
barrier (371, 372). Further, activation of the canonical WNT/TCF pathway was 
identified as a determinant of metastasis to brain and bone during lung 
adenocarcinoma progression. The WNT/TCF target genes HOXB9 and LEF1 
were identified as mediators of invasion and colonization (373).  Taken together, 
the complex interplay between various cells in the tumor microenvironment can 
play a large role in metastasis to various organs.  
 
3. Matrix Metalloproteinases in cancer and tissue remodeling 
 Growing evidence supports the notion that the matrix metalloproteinase 
(MMP) family is one of the key mediators of tumor microenvironment remodeling 
observed in metastasis. These proteinases regulate a wide array of substrates, 
thereby affecting diverse biological processes and signaling events. In addition,  
due to the poorly understood substrate repertoire, MMP inhibitors have failed in 
the clinic, and new approaches to target MMP function and regulation must be 
developed (374).   
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3.1 Matrix Metalloproteinase family members 
 When Gross and Lapiere described the “activity” capable of degrading 
collagen during tadpole tail metamorphosis (375), the MMP field was born. This 
interstitial collagenase (now known as MMP1) was then purified after being 
identified in human skin and the involuting rat uterus (376-378). Additional 
studies have led to the discovery of a family of proteinases that are structurally 
similar, comprising of 23 enzymes found in man and 24 in mice, now known as 
the matrix metalloproteinase family (311).   
 
MMPs are members of a larger family of proteases known as the 
metzincin superfamily; being zinc dependent endopeptidases with a conserved 
methionine reside in the active site (379). The MMP family shares a conserved 
domain structure, consisting of a catalytic domain and an auto-inhibitory pro-
domain (Figure 7). The pro-domain harbors a cryptic cysteine residue that keeps 
the enzyme catalytically inactive by cooperating with the zinc-containing active 
site. The catalytic domain is attached to the c-terminal domain by a flexible hinge 
linker, which is approximately 75 amino acids long, and has no determined 
structure.  In order for MMP-mediated cleavage to occur, the pro-domain must be 
removed or destabilized, allowing the catalytic site to recognize the substrate. All 
MMPs are synthesized with a signal peptide in a latent form (zymogen), which is 
then cleaved when processed through the secretory pathway. These basic 
features make up the minimal domain MMPs, MMP7 and MMP26. Despite 
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having the same minimal domain organization, MMPs are further divided into 
eight structural groups, five that are secreted and three which are bound in the 
plasma membrane, also known as the membrane-tethered MMPs (MT-MMPs) 
(380). Many MMP family members also contain a hemopexin domain, four-
bladed β-propeller structure that serves multiple functions. The hemopexin 
domain has been characterized as a mediator of protein-protein interaction, 
substrate recognition, activation of the enzyme, protease localization, 
internalization and degradation (381), including MMP1, MMP3, MMP8, MMP10, 
MMP12, MMP13, MMP19, MMP20, MMP21, MMP27, and MMP28 (311). 
MMP21 is a unique member and contains a vitronectin-like insert. MMP11 is also 
a close structural relative, but contains a furin recognition motif between the 
prodomain and the catalytic motif. This allows for intracellular activation by serine 
proteinases.  MMP2 and MMP9 are different than other MMPs having fibronectin 
type II repeats present between the catalytic and zinc-containing domains. This 
allows for gelatin substrate recognition.  The membrane tethered MMPs are 
attached to the plasma membrane either through a transmembrane domain, 
including MMP14, MMP15, MMP16, and MMP24, or by a 
glycosylphosphatidylinositol (GPI) linkage, MMP17 and MMP25, which is 
attached to the hemopexin domain. All transmembrane MMPs contain a furin-like 
recognition element. The third type has only one member, MMP23, and is a type 
II transmembrane MMP, containing an N-terminal signal anchor that targets it to 
the cell membrane, a cysteine array and immunoglobulin (Ig)-like domain (380).  
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Figure 7.  The protein structure of MMPs. The minimal-domain MMPs are secreted and 
contain an amino terminal signal sequence (Pre) which directs them to the endoplasmic 
reticulum, a pro-domain (Pro) which contains a thiol group, and a catalytic domain with a 
zinc binding site. These include MMP7 and MMP26. The MMPs that have a hemopexin 
domain (purple) contain a linker (red). MMP1, 3, 8, 10, 12, 13, 18,19, 20, 22, and 27 
belong to this subclass. MMP2 and MMP9 contain repeats of fibronectin (orange) to 
mediate gelatin recognition. MMP11 and MMP28 are the furin activated secreted MMPs, 
and contain a furin recognition sequence for intracellular furin-mediated cleavage. 
MMP21 contains a vitronectin-like insert, in addition to furin. The transmembrane MMPs, 
MMP14, MMP15, MMP16, and MMP24 contain a transmembrane domain and a short 
cytoplasmic domain; MMP17 and MMP25 are anchored by a 
glycosylphosphatidylinosition residue. MMP23 is the only member of the type II 
transmembrane subclass, and contains a signal anchor in the amino terminus (SA) and 
a cysteine array with an Ig-like domain in the carboxy terminus. 
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3.2 MMP substrates and functions 
 Although MMP1 was initially named an interstitial collagenase due to its 
simple role of degrading collagen, the remainder of the MMP family seems to 
have varying degrees of promiscuity with biological substrates. Historically, the 
MMPs were named according to what component of the ECM they could 
degrade: collagenases, gelatinases, stromelysins, and matrilysins (380). In fact, 
most extracellular signaling events take place at the cell surface, where MMPs 
are either secreted, or tethered at the membrane to aid in pericellular proteolysis.  
 
3.2.1 MMPs regulate signaling molecules 
It is true that MMPs collectively can degrade all components of the ECM, 
however sometimes the cleavage can generate products with new functions. For 
example, the cleavage of laminin-5 and collagen type IV can result in exposure of 
cryptic sites that promote migration (382, 383). Similarly, cleavage of IGF-BP and 
basement membrane-specific heparan sulfate proteoglycan core protein (HSPG) 
can release IGF and FGFs, respectively (384, 385). Other cell adhesion 
molecules like E-cadherin, desmogleins and CD44 are cleaved by MMPs, 
yielding an increase in invasive behavior (386-388).  
 
 MMPs also function by activating inactive growth factors. For example, 
transforming growth factor α (TGFα) is activated after shedding its ecto-domain 
in an MMP-dependent manner (389). TGFβ can be activated by either MMP2 or 
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MMP9, but in a different way—it is freed from extracellular space, and then able 
to engage its cognate receptors (390). In drosophila, MMP1 releases the N-
terminal extracellular domain of Ninjurin A (391), liberating the ectodomain, 
thereby promoting the loss of cell adhesion in a cell-nonautonomous manner. 
Further, EGFR ligands require processing by MMPs in order to function as well 
(392, 393) Growth factor receptors themselves can also be targeted by MMP2: 
FGFR1, HER2, HER4, and c-MET are all processed by an unidentified MMP or 
ADAM family member which is responsive to endogenous inhibitors of MMP 
activity, the tissue inhibitors of metalloproteinases (TIMPs) (394-396).  
 
3.2.2 MMPs regulate apoptosis 
There is also evidence that MMPs aid in evading apoptosis. Apoptosis is 
frequently initiated via extracellular receptors such as the Fas receptor, which 
can then activate the proteolytic cascade of intracellular caspases. MMPs might 
function by cleaving ligands, and inactivating those signals, or cleavage of 
extracellular receptors making them unable to engage ligands. For example, 
MMP7 cleaves Fas ligand in doxorubicin treated cancer cells, hindering the 
efficacy of the chemotherapy (397). MMP3 could induce apoptosis when 
overexpressed in epithelial cells (398, 399). MMP11 seems to also play a role; it 
can inhibit apoptosis when overexpressed in xenografts (400, 401) and MMP11 
null mice have a high rate of apoptosis (402) coupled with delayed mammary 
tumorigenesis (403). Adding to the complexity, it seems that MMP9 and MMP11 
activity might increase apoptosis rates during development, whereas they 
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decrease cancer cell apoptosis (404, 405). MMP8 may have a specialized role in 
apoptosis of the skin, since MMP8 null mice have an increased incidence of skin 
tumor formation (406).  
 
3.2.3 MMPs regulate angiogenesis 
The role of MMPs in normal vasculature and cancer vasculature is 
significant. MMP inhibitors reduce angiogenesis (407-409), although this could 
be attributed to less degradation of the ECM by inhibiting MMP1 cleavage of type 
I collagen in the interstitial parenchyma (410). MMP2 loss appears to directly 
down regulate angiogenesis in several in vivo models, including the chick 
chorioallantoic membrane model (CAM) (411), and in MMP2-deficient mice 
(412).  MMP9 is also required for angiogenesis in animal models of skin cancer 
(413) and insulinoma, partially by increasing the bioavailability of VEGF (414). 
Further, MMP9 and MMP14 null mice have impaired vessels formation during 
development (405, 415). MMPs can also cleave plasminogen to generate 
angiostatin (416). Angiostatin is a potent inhibitor of endothelial cell proliferation 
and invasion through inhibition of MMP14 and MMP2 (417-419).  
 
3.2.4 MMPs regulate invasion and metastasis 
Collectively, the MMP family is able to degrade every component of the 
ECM; they are crucial proteins for the invasion and metastasis of tumor cells. 
This has been shown in both in vitro and in vivo metastasis assays. MMP2 (420), 
MMP3 (421), MMP13 (422), and MMP14 (423) promote invasion of cell lines 
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through collagen type I optic nerve explant models or through matrigel.  MMP2 
and MMP9 contribute to prostate cancer cell invasion by ADAM17-mediated 
shedding of TGF-α, which subsequently activates the EGFR-MEK-ERK signaling 
pathway (424). A potent fibrinolytic enzyme, MMP16, induced efficient invasion of 
cells in fibrin, a provisional matrix component frequently found at tumor-host 
tissue interfaces and perivascular spaces of melanoma. However, MMP16 did 
not demonstrate the same type I collagen degradation activity as MMP14 (425). 
MMP10 plays an important role in the invasion and metastasis of head and neck 
squamous cell carcinoma, and that invasion driven by MMP10 is partially 
associated with p38 MAPK inhibition (426). Further, MMP9-dependent migration, 
invasion, and angiogenesis of breast carcinoma cells are dependent on 
cholesterol levels in lipid rafts to elicit activities (427). In order for cells to migrate 
freely, they must detach themselves from other cells. For this purpose, E-
cadherin is cleaved by MMP3 and MMP7, pushing cells towards EMT (386).  
 
CD44 is cleaved by MMP14, and the extracellular domain is freed (387). 
CD44 can also tether MMP9 to the cell surface to aid in pericellular proteolysis 
(428). When CD44 cannot bind to MMP9, there is less invasion in vivo 
suggesting that it is not the expression level of MMPs that mediates invasion, but 
rather the localization. Conversely, in vitro overexpression studies have shown 
that high MMP2 levels do not confer a more invasive phenotype (420). In addition 
to utilizing proteolysis to degrade the ECM, cells develop specialized invasion 
edges known as invadopodia (429). MMP2, MMP9, and MMP14 have been 
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shown to localize to invadopodia, though the exact mechanisms for this 
localization are still unclear. Although only observed in a rodent model of prostate 
cancer, MMP7 expressed by osteoclasts at the tumor/bone interface triggers 
bone metastasis through RANKL (430).  
 
MMP14 seems to be the climacteric protease for tumor cell invasion in 
most in vitro and in vivo studies (431). It has been shown to drive single-cell and 
subsequent collective cell migration and invasion (432). MMP14 is crucial for 
collagen turnover, as a collagen degradation enzyme, and through the activation 
of other MMPs (324, 433). Further, in the chick chorioallantoic model of invasion, 
when MMP14 and MMP15 null mouse fibroblasts are plated on top of the CAM, 
there is no definitive invasion (434). Later studies identified a triad of membrane-
anchored proteases, MMP14, MMP15, and MMP16 as proteins responsible for 
invasive pseudopodia, and propagation of transmigration (435). However 
targeting MMP14 to inhibit metastasis is not simple, since MMP14 appears to 
also be the most nonredundant protease for tissue homeostasis. MMP14 null 
mice have multiple organ defects that ultimately lead to death in several months 
(436-439).  Taken together, the MMP proteins can regulate multiple processes, 
leading to tumor initiation and progression of cancer.   
 
3.3 Regulation of MMP activity 
The regulation of MMP activity is difficult to assess due to the multitude of 
mechanisms affecting bioavailability of these enzymes. The easiest way to 
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assess total MMP levels is by analyzing the mRNA transcript, rather than the 
protein or enzyme-activity level, due to complex protein regulation. In addition to 
the transcriptional regulation of MMPs, they are regulated at the translational 
level, through intracellular trafficking and secretion, by subcellular or extracellular 
localization, through zymogen activation, by binding to endogenous inhibitors 
including TIMPs and α2-macroglobulin, and finally through degradation by 
proteases (440). The most studied endogenous MMP inhibitors are the TIMP 
family, TIMP1, -2, -3, and -4, which can reversibly inhibit MMPs in a 1:1 ratio. 
Like the MMP family, their expression is variable between tissue types.  
 
At the level of transcription, validated promoter analysis and bioinformatics 
approaches have revealed that each MMP promoter is unique (441). Many 
promoters have been validated to reveal a variety of functional cis-elements, 
including the first identified site in the MMP1 promoter coding for AP-1, a 
member of the immediate-early response genes (442). In many promoters with 
AP-1 sites, there is also a PEA-3 binding site nearby, and can act in concert with 
AP-1. Many MMPs also have GC boxes in their proximal promoters, which can 
bind to Sp1, Sp3 and potentially other GC-binding proteins as well (441).  Many 
MMPs show constitutive expression. MMP14 has a proximal Sp1 site, and 
mutation of this site severely reduces the activity (443).  Egr1 has also been 
shown to regulate MMP14 through binding of conserved GC rich regions of the 
promoter (444). NFκB can also regulate many MMP genes including MMP9 (445, 
446), MMP1 (447), and possibly many others bearing canonical NFκB binding 
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sites (441). Our studies indicate a novel role for E2F transcription factors in 
regulation of at least MMP2, MMP9, MMP14, and MMP15, though all 23 human 
MMP family members contain putative E2F binding sites (448).  Given that 
aberrant E2F activity is observed in many cancers, we hypothesize that through 
transcriptional regulation of MMPs, E2Fs might also function to promote 
metastasis.  
 
4. Summary 
  Rb together with E2F transcription factors is a crucial regulator of the cell 
cycle, and many other biological functions. Rb physically interacts with E2F, 
repressing its ability to both recruit transcriptional machinery, and by retaining an 
Rb-E2F complex on E2F responsive promoters (449). Not surprisingly, 
oncogenic mutations can initiate tumors by targeting the Rb-E2F pathway and 
this pathway is altered in many cancers, including non-hereditary tumors. Though 
disruption of the Rb-E2F pathway has a clear role for initiating oncogenesis, it is 
unclear whether this pathway contributes to cancer progression, angiogenesis 
and metastasis.  
 
  It is well established that cyclin-dependent kinases phosphorylate and 
inactivate Rb in the G1 phase of the cell cycle, which releases E2F transcription 
factors from Rb, facilitating transcriptional induction of proliferative promoters 
(121). Raf-1 directly interacts with Rb early in the cell cycle. Further, Raf-1 can 
phosphorylate Rb (36). Rb-Raf-1 disruptor (RRD-251), can disrupt the Rb-Raf-1 
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interaction, suppressing the phosphorylation of Rb. RRD-251 can affect many 
facets of cancer, including proliferation, cell cycle control, and angiogenesis. 
Importantly, it is effective at inhibiting tumor growth in vivo, though the exact 
mechanism for these effects has yet to be investigated on the molecular level 
(39).  
 
 In most clinical cancer cases, metastasis is associated with late-stage 
oncogenic events, tumor progression, and eventual death. Despite the pastiche 
of mutations that give rise to tumors, which varies greatly between tumor types, 
the steps that drive efficient tumor cell dissemination remain similar for all tumors 
(450). This suggests that clinically targeting proteins involved in the metastatic 
cascade could be an efficient mode to treat cancer from disparate genetic and 
tissue origin. The complex interaction between cell types in the tumor 
microenvironment, including tumor cells, stromal fibroblasts, tumor associated 
macrophages, immune cells, and bone-marrow derived stem cells, epithelial 
progenitor cells, and their individual contributions make studying metastasis in 
vitro quite daunting (451).  
 
Studies showing the overexpression of MMPs in a variety of cancer types 
have lead to a strong effort in the development of MMP inhibitors (MMPis) since 
the 1980s (452-454). Due to the broad spectrum of substrates, both known and 
unknown that are cleaved by MMPs, including essential immune regulating 
chemokines and cytokines, the failure of large-scale Phase III clinical trials is not 
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surprising.  In the following chapters, we describe studies that link the Rb-E2F 
pathway and upstream regulation by the Raf-1 kinase, to regulation of MMP gene 
expression and subsequent metastasis and colonization. These studies not only 
link early oncogenic events to late stage events in the oncogenic process, but 
they also highlight the Rb-Raf-1 disruptor, RRD-251, as a viable 
chemotherapeutic that can target multiple hallmarks of cancer.   
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Chapter 2: Materials and Methods 
Cell Lines and Reagents 
 A549 NSCLC cells were cultured in F12K medium with 10% serum 
(Cellgro). MDA-MB-468, MDA-MB-435, T47D and MDA-MB-231 human breast 
cancer cell lines were cultured in Dulbecco modified Eagle Medium (DMEM; 
Mediatech) containing 10% FBS. H1299, H358, H1975, and H1650 human 
NSCLC cells were grown in RPMI with 10% serum. A549 cells stably expressing 
the firefly luciferase gene (A549-luc) were obtained from Caliper and grown in 
RPMI with neomycin (200 ng/mL). ShRNA cells lines were maintained in media 
containing 0.5 µg/ml puromycin. For treatment with RRD-251, cells were 
rendered quiescent by serum starvation for 18 hours, and then grown in 10% 
serum-containing in F12K medium with RRD-251. The Rb-Raf disruptor, RRD-
251, was prepared as described and was >99% pure as analyzed by HPLC. 
Nicotine (Sigma) was dosed at 1 µM concentration for all nicotine experiments.  
Twenty-four hours after luciferase constructs were transfected, suberoylanilide 
hydroxamic acid (Vorinostat, or SAHA) and trichostatin A (TSA) (Cayman 
Chemicals) were dosed at 50 nM in respective media for 24 hours. For treatment 
with (±)-Nutlin-3 (Cayman Chemicals), cells were treated with drugs for 72 hours 
at indicated concentration. ShRNA cell lines were made by stably transfecting 
  
59 
A549 cells with two different shRNA constructs that specifically targeted E2F1 or 
E2F3 obtained from an shRNAmir library from Open Biosystems, Huntsville, AL. 
 
Molecular cloning and constructs 
  DNA was extracted from primary aortic endothelial cells using standard 
protocols (36). Primers spanning 2 Kb of the MMP9 and MMP15 promoter were 
used to PCR amplify the fragment with Hotmaster Taq (5-Prime). Primer 
sequences were:  
5’-TACGGTGCTTGACACAGTAAATC-3’ (MMP9 forward); 
5’-CTGACTGCAGCTGCTGTTGTGG-3’ (MMP9 reverse); 
5’-GCTACTTTCCTTCACTGAACAGG-3’ (MMP15 forward); 
5’-CGAGTGAAGTGCGACAGTGCGGCC-3’ (MMP15 reverse). 
The fragments were then subcloned into pCR2.1 using TA cloning (Invitrogen).  
The plasmids were digested with Kpn1 and Xho1 and ligated into pGL3-basic 
luciferase vector (Promega). The MMP14 promoter was a kind gift from Dr. 
Jouko Lohi at The University of Helsinski (443).  The MMP2 promoter was a gift 
from Dr. Etty Benveniste at The University of Alabama. For the generation of 5’ 
deletion mutants, the following primer sequences were used to PCR amplify from 
the original full length MMP2-luc construct DNA:  
5’-GACCCAAGCCGCAGAGACTTTTC-3’ (∆1617F); 
5’-CTTCCTAGGCTGGTCCTTACTGAC-3’ (∆1467F);  
5’-GCCATGGCACTGGTGGGTGCTTC-3’ (∆945F);  
5’-CCATCTCTCTCTTTCCATCTCTG-3’ (∆508F);  
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5’-GTGACGAGGTCGTGCACTGAGGGT-3’ (∆221F)   
5’-CAGATGCGCAGCCTCCAGCCAC-3’ (R). The fragments were then 
subcloned into pCR2.1 using TA cloning (Invitrogen).  The plasmids were 
digested with Kpn1 and Xho1 and ligated into pGL3-basic luciferase vector 
(Promega). The following primers were used with overlap extension PCR to 
incorporate a c-MYC, p53, or E2F binding site mutation into the MMP2-luc 
construct. For c-MYC: 
5’-CTTCCTAGGCTGGTCCTTACTGAC-3’- F1 
 5’CAAGAATCCACCTGGCCTCTCAGG-3’-R1-OEPCR-MYCmut 
5’-CCTGAGAGGCCAGGTGGATTCTTG-3’-F2-OEPCR-MYCmut 
5’-CAGATGCGCAGCCTCCAGCCAC-3’ – R2  
For p53 and E2F1: 
5’-CTGCGGGGCAAGGTCCCTC-3’-F1 
5’-GTGGGCTTCAGAAAATTTCAGGATTTTC-3’-R1-OEPCR-p53mut 
5’-GAAAATCCTGAAATTTTCTGAAGCCCAC-3’- F2-OEPCR-p53mut 
5’-AAGCCCCAGATGCGCAGCCTCCAGCCAC-3’-R2 
5’-GCCGCAGAGACTTCGATAGATGTGA-F2-3’-OEPCR-E2Fmut 
5’-TCACATCTATCGAAGTCTCTGCGGC-R1-3’-OEPCR-E2Fmut. For overlap 
extension PCR, 3 rounds of amplification are used; primers F1 and R1and 
primers F2 and R2 are used to first generate two fragments containing the 
mutation. This DNA is then pooled and used for a third round of amplification, 
where primers F1 and R2 are used, generating the full length product with the 
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mutation incorporated. To ensure a proper clone was developed, DNA 
sequencing was performed.  
 
Transient transfections and Luciferase Assays 
  Eighty-five thousand cells were plated per well in six well plates, grown to 
70% confluency, then were transfected with 0.5 µg of MMP-luciferase reporters 
along with 1 µg of E2F1, 2 µg of Rb-Large Pocket or full length, and 2 µg of Raf-1 
full length expression vector using Fugene HD reagent in a ratio of 4 µl of 
Fugene (Roche and Promega) to 2 µg of plasmid. For the transfection of c-MYC, 
ID1, p53, p300, MDM2, or KAP1, 1 µg of plasmid was used unless otherwise 
indicated. Cotransfection with 0.5 µg of pRL construct containing Renilla 
reniformis luciferase gene was used as normalizing control. Luciferase assays 
were performed using Dual Luciferase Assay System (Promega). Relative 
luciferase activity was defined as the ratio of firefly luciferase activity to Renilla 
luciferase activity. Error bars represent standard deviation of three experiments.  
 
Gelatin Zymography 
  Media was concentrated using 7 kD molecular weight cut off protein 
concentrators at 4oC (455) and subjected to electrophoresis on 8% 
polyacrylamide gels containing 2 mg/mL bovine skin gelatin (Sigma). Gels were 
washed twice with 2.5% Triton-X100, and then incubated for 24 hours at 37o C in 
Tris-HCl buffer (150 mM NaCl, 10 mM CaCl2, 50 mM Tris-HCl pH7.6 and 0.05% 
NaN3). Gels were stained with 0.2% Coomassie Brilliant Blue and destained 
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(30% methanol, 10% glacial acetic acid, and 60% H20) until gelatinolytic bands 
could be detected. Gelatinolytic signals were quantified by densitometry. 
 
Chromatin immunoprecipitation (ChIP) assays 
 Cells were treated with 1% formaldehyde for 10 minutes at room temperature 
for cross-linking the DNA to the proteins. The cells were scraped, washed in ice-
cold PBS, and centrifuged at 1500 x g at 4°C for 5 minutes. Subsequently, the 
pellet was resuspended in cell lysis buffer (44 mM Tris–HCl (pH 8.1), 1% SDS, 1 
mM EDTA (pH 8.0)). The cells were sonicated thrice for 15 seconds each. 
Subsequently, the cell lysates were centrifuged at 10,000xg at 4°C for 15 
minutes. An aliquot of the sonicated DNA was used as the input for the ChIP 
assay. The remainder of the chromatin was diluted with ChIP dilution buffer (16 
mM Tris–HCl (pH 8.1), 250 mM NaCl, 0.1% SDS, 1% Triton-X-100, 1.2 mM 
EDTA) and rotated overnight with primary antibody. Immunoprecipitations were 
done using polyclonal antibodies for E2F1-5 and Rb (Santa Cruz), p53, HDAC1, 
MDM2, monoclonal (Santa Cruz) and KAP1 polyclonal (Bethyl); a Rabbit anti-
mouse secondary antibody (455) was used as the negative control. The next 
day, 60 µL of 1:1 protein G-Sepharose was added to the immune complexes, 
and the mixture was rotated at 4°C for 2 hours. The  beads were washed five 
times with ChIP dilution buffer and eluted with ChIP elution buffer (0.1 M sodium 
bicarbonate, 1% SDS, 5 mM NaCl). The cross-links were reversed by incubation 
at 65°C for 4 hours. DNA was isolated by ethanol pr ecipitation. The associated 
proteins with the DNA were digested with 50 µg Proteinase K at 37°C for 30 
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minutes. DNA was purified by phenol:chloroform extraction method followed by 
ethanol precipitation. Purified DNA was resuspended in 30 µL water. The 
differential binding between proteins and MMP2, MMP9, MMP14, MMP15, 
DHFR, CDC6, CDC25a, and c-FOS promoter DNA was examined by polymerase 
chain reaction (PCR). For ChIP assays after nicotine stimulation, quiescent A549 
cells (2.5 × 107) were incubated with 1 µM nicotine at 37°C for 48 hours. The 
interaction with specific promoters was detected using PCR with primer 
sequences from Table 1. For all ChIP assays throughout this manuscript, ChIP 
assays were conducted using primer sequences listed. The binding sites listed 
represent binding elements upstream of TSS. 
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Table 1. Primer Sequences used in ChIP assays.  
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siRNA transfections and Real-time PCR 
  For siRNA transfections 100 pmol of siRNAs (Santa Cruz) with 
Oligofectamine were added to cells. For real-time PCR, total RNA was isolated 
using RNeasy miniprep kit (QIAGEN) following manufacturer's protocol, followed 
by first-strand cDNA synthesis using iScript cDNA synthesis kit (Bio-Rad). Data 
was analyzed by ∆∆CT method, where gene of interested was normalized to 18S 
rRNA, then compared to the non-targeting siRNA control sample. Error bars 
represent the standard deviation of three independent experiments. 
 
Invasion Assays 
  Boyden Chamber assays were used to assess the invasive ability of A549, 
and MDA-MB-231 cells as described previously (37, 456). The upper surface of 
the 6.5 mm filters (Corning) were coated with collagen (100 µg/filter) and Matrigel 
(BD Bioscience) (50 µg/filter). Twenty thousand cells were plated in the upper 
chamber with 0.1% bovine serum albumin (Sigma). Media containing 20% fetal 
bovine serum was placed in the lower well as chemoattractant. The cells that 
invaded through the filters were quantified by counting three fields under 20× 
objective magnifications.   
   
Would healing assays 
  One hundred thousand A549 cells were plated in a 6-well plate and grown 
to confluency (457). The cells were scratched with a sterile 200 µl pipette tip in 
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three separate places in each well, placed in serum-free media as a negative 
control, stimulated with 10% serum, or 10% serum with 50 µM RRD-251, and the 
same area was examined after 24 hours using phase contrast microscopy (41). 
Similar experiments were performed with H1650, MDA-MB-468, and MDA-MB-
231 cells. The data is representative of three independent experiments. For 
experiments with Mitomycin C, cells were treated with 10 mg/mL of Mitomycin C 
for 5-12 hours, then placed back in 10% serum containing media. For siRNA 
studies, A549 cells were plated at 50% confluency (eighty thousand cells) then 
transfected with siRNA targeting E2F1, E2F3 or combination of both (Santa 
Cruz). Cells then grew for 24 hours before being scratched with a pipette tip. 
Migration assays were quantified using Alpha Imager analysis software. 
 
Collagen Degradation Assays 
  Collagen Degradation Assays were carried out as previously described 
(458). First, 1 mL of type I collagen was mixed with 7 mL of 13 mM HCl, then 
neutralized with a buffer containing 0.2 M NaPO4, 16.6 mL 5M NaCl, 80 mL 0.1 N 
NaOH . Seven hundred µl of this solution was added to 12-well tissue culture 
plates to obtain a final concentration of 1 µg/mL of collagen. Plates were 
incubated at 37oC for 2 hours to polymerize. Twenty-five thousand CCL-210 cells 
were placed in a 40 µl button and were left to attach 5 hours at 37oC. Complete 
media was added, and after 4 days, cells were trypsinized, and the remaining 
collagen was stained with Coomassie Brilliant Blue for 15 minutes, and then 
destained (30% methanol, 10% glacial acetic acid, 60% H20).  For siRNA 
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experiments, eighty-five thousand CCL-210 cells were plated in 60 mm plates, 
then transfected with 100 pmol of siRNA (Santa Cruz). Twenty-four hours later, 
twenty-five thousand cells were added to the collagen films. For RRD-251 
studies, cells were pretreated for 18 hours prior to being placed on collagen films. 
For nicotine studies, cells were plated on collagen, and placed in nicotine-
containing media immediately following attachment to collagen. Images were 
taken using Epson Perfection V700 Photo Scanner.   
 
Proliferation Assays 
  Bromodeoxyuridine (BrdU) labeling kits were obtained from Roche. Cells 
were plated in poly-D-lysine coated chamber slides at 6,000 cells/well and serum 
starved for 24 hours. Cells were then stimulated with serum in the presence or 
absence of 10 µg/mL Mitomycin C for 3 hours, and then incubated in complete 
media. S-phase cells were visualized by microscopy and quantified by counting 
three fields of 100 in quadruplicate.   
 
In vivo tail vein metastasis assay 
  Five million A549 cells stably expressing firefly luciferase (A549-Luc-C8) 
(Caliper) were injected into the lateral tail vein of 5-week-old female SCID-beige 
mice under an IACUC approved protocol. Mice were given DPBS: DMSO vehicle 
control or RRD-251 diluted with DPBS: DMSO once/day. For bioluminescence 
imaging, mice were anesthetized and 30 mg/Kg of D-luciferin in PBS was 
administered by intraperitoneal (i.p.) injection. Ten minutes after injection, 
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bioluminescence was imaged with a charge-coupled device camera (Caliper). 
Bioluminescence images were obtained with a 15 cm field of view, binning 
(resolution) factor of 8, 1/f stop, open filter, and an imaging time of 30 s to 2 min. 
Bioluminescence from relative optical intensity was defined manually, and data 
were expressed as photon flux (photons·sec−1·cm−2·steradian−1) and were 
normalized to background photon flux over a mouse that was not given an 
injection of luciferin.  
 
Immunoprecipitation and Immunoblotting 
Cell lysates were made from exponentially growing cultures of A549, 
H1650, MDA-MB-231, and MCF7 cells in respective medium by adding lysis 
buffer (20 mM Tris–HCl (pH 7.6), 0.5% Nonidet-40 (new name IGEPAL-CA-630), 
250 mM NaCl, 3 mM EGTA, 3 mM EDTA, 4 µM dithiothreitol (DTT), 5 mM 
phenylmethylsulfonylfluoride (PMSF), 1 mM sodium fluoride, 1 mM sodium 
orthovanadate, 25 µg/mL leupeptin, 5 µg/mL pepstatin, 5 µg/mL aprotinin, 25 
µg/mL trypsin–chymotrypsin inhibitor) to 20 µL of packed cell volume. The lysate 
was rotated at 4°C for 30 minutes and subsequently centrifuged at 15,000g at 
4°C for 15 minutes. The protein concentration was m easured using a Bio-Rad 
Protein Assay Kit.  
 
  For co-immunoprecipitation, the cell lysates containing 250-1000 µg of 
total proteins were incubated with 1 µg of the following antibodies: Mouse anti-
human c-MYC, mouse anti-human HDAC1, and rabbit anti-human KAP1. The 
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total reaction volume was adjusted to 100 µL with immunoprecipitation buffer (2 
mM HEPES (pH 7.9), 40 mM KCl, 0.001 mM MgCl2, 25 mM EGTA, 1 mM EDTA, 
1% IGEPAL-CA-630, 1 mM DTT, 5 mM PMSF, 1 mM sodium fluoride, 1 mM 
sodium orthovanadate, 25 µg/mL leupeptin, 5 µg/mL pepstatin, 5 µg/mL 
aprotinin, 25 µg/mL trypsin–chymotrypsin inhibitor) and rotated on a nutator at 
4°C for 2 hour. After 1 hour, 50 µL of 1:1 protein G-Sepharose, or protein A-
Sepharose slurry was added (GE Healthcare) and the mixture was rotated at 4°C 
for another 3 hours. The beads were washed four times in immunoprecipitation 
buffer. Bound proteins were eluted in sodium dodecyl sulfate (SDS) sample 
buffer (0.06 M Tris–HCl (pH 6.8), 10% glycerol, 2% SDS, and 100 mM DTT, 
0.2% w/v bromophenol blue) and resolved on an 8% SDS–polyacrylamide gel. 
The proteins on the SDS–polyacrylamide gel were transferred to 0.45 µm 
nitrocellulose membranes (Bio-Rad), and the interacting proteins were detected 
by immunoblotting as described below. As a control for the experiment, one-third 
of the amount of protein was analyzed on the SDS–polyacrylamide gel for each 
immunoprecipitation reaction. 
 
For immunoblotting, nitrocellulose membranes were incubated in a 
blocking solution containing 5% nonfat dry milk in PBS containing 0.1% Tween-
20 at room temperature for 1 hour. Membranes were incubated at 4°C overnight 
with indicated primary antibodies followed by incubation with horseradish 
peroxidase–conjugated anti-mouse IgG or anti-rabbit IgG (1:3000 dilution) at 
room temperature for 2 hour. Antibody–protein complexes were detected using 
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enhanced chemiluminescence immunoblotting detection reagent (GE 
Healthcare). The immunoblot signals were quantified using Alpha Imager HP gel 
documentation system. The experiment was performed twice with two 
independent sets of cell lysates and tumor lysates. 
 
Tissue Processing and Immunohistochemical Staining 
 Lungs were fixed in 10% neutral buffered formalin after necropsy, before 
processing into paraffin blocks. Paraffin sections (5-Am thick) were rehydrated 
and processed using hematoxylin and eosin staining with standard techniques. 
For other studies, paraffin sections were deparaffinized by baking at 62°C for 1 
hour and then immersed twice in 100% xylene at room temperature for 10 
minutes each, followed by incubating in 100% ethyl alcohol for 10 minutes, and 
rehydrated with decreasing concentrations (90%, 80%, 70% and 50%; vol/vol in 
water) of ethyl alcohol for 5 minutes each. Sections were rinsed in dH2O, and 
then subjected to microwave antigen retrieval in 0.01 M sodium citrate, pH 6.0 for 
20 minutes on 70% power, with a 30-minute cooling period. Sections were rinsed 
3 times in dH2O, twice in PBS and then staining was done according to 
manufacturer’s protocol (VECTASTAIN Elite ABC Kit, Vector Laboratories). The 
kit contained blocking serum, secondary antibody and avidin–biotin–horseradish 
peroxidase complex. The slide was blocked with blocking horse serum for one 
hour at room temperature followed by incubation with primary antibody for 
HDAC1 (1:3000 dilution; Ed Seto Lab) or KAP1 (1:4000; Bethyl) at 4°C, 
overnight. The slide was rinsed three times in PBS for 10 minutes each and 
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incubated with secondary antibody for one hour at room temperature. Following 
three rinses in PBS for 10 minutes each, the slide was incubated with avidin–
biotin–horseradish peroxidase complex for 30 minutes at room temperature. To 
detect the bound antibody, the slide was treated with peroxidase substrate kit 
(Vector Laboratories), wherein 3,3′-diaminobenzidine (459) was the chromogen, 
and color developed within 5 minutes of adding the DAB solution. After a final 
rinse in distilled water, sections were lightly counterstained in hematoxylin, 
dehydrated by immersing in increasing concentrations of ethyl alcohol (50%, 
70%, 80%, 90%, and 100%; vol/vol in water) for 3 minutes each and finally 
immersed in 100% xylene twice for 2 minutes each. The slides were mounted in 
Clarion mounting medium (Santa Cruz Biotechnology). Immunostained slides 
were scanned using the Aperio Automatic Scanning System from Applied 
Imaging (San Jose, CA). The experiment was repeated three times. 
 
Immunofluorescence and confocal microscopy 
A549, H1650, MCF-7 and MDA-MB-231 cells were plated onto poly-D-
lysine-coated eight-well glass chamber slides (5,000 cells per well) for 
immunostaining. The cells were fixed with 10% buffered-formalin and double 
immunofluorescence was performed as per the protocol published previously 
(48). Primary antibodies used were monoclonal c-MYC (cell signaling; 1:200) 
monoclonal HDAC1 (Santa Cruz; 1:200) and rabbit monoclonal ID1 (Biocheck; 
1:3000) or polyclonal KAP1 (Bethyl; 1:4000). Secondary antibodies were goat 
anti-rabbit Alexa Fluor-594 and anti-mouse Alexa Fluor-488 (Molecular Probes) 
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respectively. DAPI (Vector labs) was used to stain the nuclei. Cells were 
visualized with a DM16000 inverted Leica TCS SP5 tandem scanning confocal 
microscope. Images were produced with three cooled photomultiplier detectors 
and analyzed with the LAS AF software version 1.6.0 build 1016 (Leica 
Microsystems, Germany). 
 
In vivo orthotopic metastasis assay 
  For orthotopic transplantation of A549-luciferase cells, 250,000 cells/100 
µl were injected into the right lung of SCID-beige mice. Mice are anesthetized by 
gas anesthesia (3% isoflurane). Thirty gauge needles were used in an open 
technique where cells were implanted into the right lung. For injection, mice were 
placed in the left lateral decubitus position with a 15 ml conical placed under the 
animal to expose the thoracic rib cage. A small posterolateral incision, 5-7 mm 
was made at the lateral dorsal axillary line, just below the inferior border of the 
scapula. The needle was inserted between the 4th and 5th intercostals spaces 
and placed 5 mm into the thoracic cavity before injection of cell slurry. Skin and 
subcutaneous tissue is closed by staple. Mice were imaged 6 hours after surgery 
to monitor implantation of cells with IVIS-100 (Caliper).  
 
  For bioluminescence imaging, mice were anesthetized and 30 mg/Kg of 
D-luciferin in PBS was administered by intraperitoneal (i.p.) injection. Ten 
minutes after injection, bioluminescence was imaged with a charge-coupled 
device camera (Caliper). Bioluminescence images were obtained with a 15 cm 
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field of view, binning (resolution) factor of 8, 1/f stop, open filter, and an imaging 
time of 30 s to 2 min. Bioluminescence from relative optical intensity was defined 
manually, and data were expressed as photon flux (photons·sec−1 
·cm−2·steradian−1) and were normalized to background photon flux over a mouse 
that was not given an injection of luciferin. 
 
  For nicotine studies, the mice were randomized 3-7 days after injection of 
tumor cells. Mice were separated into two groups Vehicle (n=6) and Nicotine 
(n=6). Mice received nicotine by i.p. injection at a dose of 1 mg/kg three times a 
week. Mice were imaged for increase in bioluminescence once/week for five 
weeks. At the completion of the experiment, vital organs were collected, and 
imaged ex vivo by placing dissected organs in luciferin solution.  
 
Statistical analysis 
  Statistical analysis was performed using one-tailed Student’s t test. Values 
were considered significant when the P value was <0.05. 
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Chapter 3: Regulation of Matrix Metalloproteinase Genes by E2F 
transcription factors: Rb-Raf-1 interaction as a novel target for metastatic 
disease 
 
Abstract 
The Rb-E2F transcriptional regulatory pathway plays a major role in cell cycle 
regulation, but its role in invasion and metastasis is less understood. We find that 
many genes involved in the invasion of cancer cells, such as matrix 
metalloproteinases, have potential E2F binding sites in their promoters. E2F 
binding sites were predicted on all 23 human MMP gene promoters, many of 
which harbored multiple E2F binding sites. Studies presented here show that 
MMP genes such as MMP9, MMP14, and MMP15, which are overexpressed in 
non-small cell lung cancer (NSCLC) have multiple E2F binding sites and are 
regulated by the Rb-E2F pathway. Chromatin immunoprecipitation assays 
showed the association of E2F1 with the MMP9, MMP14, and MMP15 promoters 
and transient transfection experiments showed that these promoters are E2F 
responsive. Correspondingly, depletion of E2F family members by RNAi 
techniques reduced the expression of these genes with a corresponding 
reduction in collagen degradation activity. Further, activating Rb by inhibiting the 
interaction of Raf-1 with Rb using the Rb-Raf-1 disruptor RRD-251 was sufficient 
to inhibit MMP transcription. This led to reduced invasion and migration of cancer 
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cells in vitro and metastatic foci development in a tail vein lung metastasis model 
in mice. These results suggest that E2F transcription factors may play a role in 
promoting metastasis through regulation of MMP genes, and that targeting the 
Rb-Raf-1 interaction is a promising approach for the treatment of metastatic 
disease. 
 
Introduction 
  The retinoblastoma tumor suppressor protein, Rb, together with the E2F 
transcription factors is the main regulator of the mammalian cell cycle (66). Rb 
physically interacts with E2Fs 1-3 via their transcriptional activation domain, 
repressing their transcriptional activity (460). In response to mitogenic signaling, 
Rb is inactivated in the G1 phase of the cell cycle in multiple waves of 
phosphorylation by cyclin-dependent kinases 2, 4 and 6, leading to its 
dissociation from E2Fs 1-3. This facilitates the expression of various genes that 
are necessary for DNA synthesis and cell cycle progression, including cyclin E, 
dihydrofolate reductase, DNA polymerase α etc. Not surprisingly, oncogenic 
mutations target the Rb-E2F pathway to promote cell proliferation (12). The Rb 
gene itself is mutated in a variety of cancers, while mutations in signaling 
molecules like K-Ras, p16INK4 and PTEN that affect Rb function are prevalent in 
almost all cancers (12, 461, 462). This indicates a major role for the Rb-E2F 
pathway in cell cycle progression and oncogenesis. Further, E2Fs are known to 
be important for proper execution of development, differentiation, apoptosis, and 
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DNA damage repair programs (53, 449), establishing a larger role for E2Fs in the 
biology of normal mammalian cells and their transformation into cancer cells. 
 
   Our earlier studies had shown that the kinase Raf-1 physically interacts 
with Rb early in the cell cycle, facilitating Rb phosphorylation (36).  Disruption of 
the interaction of Raf-1 with Rb using the small molecule disruptor RRD-251 
prevented Rb phosphorylation, cell cycle progression, angiogenesis, and tumor 
growth in mouse models (39, 463, 464). It was found that RRD-251 could inhibit 
the expression of E2F-regulated proliferative promoters like Cdc25A and TS. 
Interestingly, recent studies from our lab have demonstrated that E2F1 could 
induce VEGF receptors, FLT-1 and KDR, indicating a role for E2F1 in tumor 
angiogenesis as well (253). Given this background, attempts were made to 
assess whether E2Fs can also affect the expression of genes involved in cell 
invasion and cancer metastasis. Towards this purpose, we used Genomatix 
MatInspector software to analyze the promoters of matrix metalloproteinase 
genes, which remodel the extracellular matrix and facilitate cell invasion and 
metastasis (374). We find that all human MMP promoters have multiple E2F 
binding sites; data presented here show that three MMPs that are overexpressed 
in NSCLC, namely MMP9, MMP14, and MMP15 are in fact E2F regulated. 
Supporting this contention, the Rb-Raf-1 disruptor, RRD-251, which prevents Rb 
phosphorylation and inhibits E2F1-mediated transcription, could inhibit the 
transcription of MMP genes. In addition, RRD-251 could prevent invasion in vitro, 
and decrease colonization of the lung in an in vivo tail vein metastasis model.  
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These results suggest that the Rb-E2F pathway contributes to the expression of 
MMP genes and that targeting this pathway might be a potential avenue to 
combat metastatic disease.  
 
Results 
MMP9, MMP14, and MMP15 promoters recruit E2F1 and Rb 
  Microarray studies had suggested that MMP genes may be E2F 
responsive (122, 258) and to explore this possibility, we examined the promoter 
region 2 Kb upstream of the transcription start site of 23 MMP genes using 
MatInspector (Genomatix) program. Putative E2F binding sites were observed on 
the promoters of all 23 MMP genes examined (Table 2. Table represents number 
of binding sites identified, location upstream of transcription start site (TSS), 
nucleotide sequence identified, and matrix score.) Since MMP9, MMP14, and 
MMP15 are overexpressed in a variety of metastatic tumors including non-small 
cell lung cancer (NSCLC), these promoters were studied further.  MMP9, 
MMP14, and MMP15 promoters had three, five, and four E2F binding sites 
respectively upstream of the TSS within the 2 Kb regions. In addition, the MMP14 
promoter had two E2F binding sites downstream of TSS (Figure 8).  
 
  ChIP assays were conducted on asynchronously growing A549 cells to 
assess whether E2F1 and Rb associate with these promoters. The location of 
primers used is shown in Figure 1A as arrows. As shown in figure 8B, there was 
a significant amount of E2F1 bound to MMP9, MMP14, and MMP15 promoters, 
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and at least two E2F binding sites recruited E2F1 on each promoter. As in the 
case of E2F-regulated proliferative promoters, Rb could also be detected on 
most MMP promoters.  E2F1 was present on three positive control promoters, 
DHFR, Cdc6, and Cdc25a. There was no Rb or E2F1 present on the unrelated c-
Fos promoter, which was the negative control. There was no DNA associated 
with an IP done with an irrelevant antibody, further establishing the specificity of 
the assay. This experiment suggests that the E2F sites present on these MMP 
promoters can recruit E2F1 and Rb.  
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Table 2. Matinspector Analysis of Putative E2F binding sites on MMP Promoters 
 
Continued on next page 
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Continuation of Table 2 
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Figure 8. MMP promoters recruit E2F1 and Rb. (A) Schematic representation of MMP9, 
MMP14, and MMP15 promoters showing potential E2F binding sites as diamond/circle 
symbols. The arrows represent the position of primers spanning E2F binding sites tested 
in ChIP assays. (B) ChIP assays conducted on asynchronously growing A549 cells 
using the indicated antibodies. Sonicated genomic DNA is used for input. The numbers 
to the right indicate the position in the promoter, in respect to TSS, where a putative E2F 
binding site was identified. C-Fos was used as a negative control, whereas DHFR, Cdc6, 
and Cdc25a are used as positive controls. Irrelevant antibody was used (Ir Ab) as a 
negative control for IP. 
B 
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MMP9, MMP14, and MMP15 promoters are responsive to  
E2F1, Rb, and Raf-1 
  Experiments were done to assess whether these E2F binding sites were 
functional. Towards this purpose, A549 cells were transiently transfected with 
luciferase reporter constructs driven by MMP9, MMP14, and MMP15 promoters. 
It was found that co-transfection of E2F1 led to a significant induction of all the 
three promoters (Figure 9A); further, co-transfection of the large pocket region of 
Rb (Rb-LP) or the full length Rb (Rb-FL) could repress the E2F1-mediated 
induction. Consistent with previous studies on proliferative E2F-target genes (36, 
38), over-expression of Raf-1 could relieve the repression mediated by Rb. 
Taken together, these results suggest that the Rb-E2F pathway might regulate 
MMP9, MMP14, and MMP15 expression.  
 
Gelatin zymography was used to determine whether overexpression of 
E2F1 enhances MMP9 gelatinase activity. Consistent with the transfection data, 
MMP9 activity was increased 1.78 fold in A549 cells and 2.54 fold in H1650s 
overexpressing E2F1 (Figure 9B-C).  This suggests that the endogenous MMP9 
promoter is responsive to E2F1 overexpression, leading to MMP9 secretion in 
cell lines.  
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Figure 9.  E2F1 induces MMP levels (A) Transient transfection experiments in A549 and 
H1650 cells showed that E2F1 could significantly (**, P<0.005; * P<0.05) induce MMP9, 
14 and 15 promoters, and this was repressed by Rb large pocket or full length Rb; co-
transfection of Raf-1 could reverse Rb-mediated repression. Control lanes include 
luciferase reporter and empty vector.  (B). Western blot shows E2F1 overexpression in 
E2F1 transfected cells compared to empty vector in A549 and H1650 cells.  (C) A549 
and H1650 cells transiently transfected with E2F1 have increased levels of MMP9 (A549 
P=0.019*; H1650 P<0.001**) gelatinase activity as seen by Coomassie stained 
zymography (inverted image).  
A 
B C 
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MMP9, MMP14, and MMP15 are induced by E2F1-5 
 Previous studies had demonstrated that proliferative promoters are induced 
mainly by the transcriptionally active family members, E2F1-3. To determine if 
MMP genes are also regulated exclusively by E2F1-3, ChIP assays were 
performed on asynchronous A549 cells. While the proliferative dihydrofolate 
reductase (DHFR) promoter recruited only E2Fs 1 and 3, E2Fs1-5 were recruited 
to the promoters of both MMP9 and MMP15 (Figure 10A); E2Fs1-4 were 
recruited to the MMP14 promoter.  Consistent with the ChIP assay data, transient 
transfection experiments on A549 cells showed that MMP promoters are 
significantly induced by E2F1-5 whereas DHFR is significantly induced by E2F1-
3 (Figure 10B-E). This data suggests that MMPs may be a new class of E2F 
target genes, which can positively respond to E2Fs 1-5.  
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Figure 10. MMP9, MMP14, and MMP15-luc are responsive to E2F1-5. (A) ChIP assays 
were carried out on asynchronously growing A549 cells. One binding site in each 
promoter was analyzed: -1920 to -1904 in MMP9; -1667 to -1532 in MMP14; and -1625 
to -1609 in MMP15. (B-E) Transient transfection experiments in A549 cells showed that 
DHFR is significantly induced by E2F1-3 (***, P<0.001; **, P<0.005; * P<0.05) though no 
significant difference with E2F4 (P=0.18) or E2F5 (P=0.47), whereas E2F1-5 could 
significantly induce all MMP promoters.  
A 
D 
E 
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E2F1, E2F3, and E2F5 are required for MMP gene expression 
  Given that E2F1-5 could induce MMP9, MMP14 and MMP15 promoters in 
transient transfections, attempts were made to assess whether E2Fs regulate the 
expression of their endogenous promoters in NSCLC cells. Towards this 
purpose, A549 and H1650 cells were transfected with 100 pMol of siRNAs to 
E2F1-5, or a non-targeting control siRNA.  Transfection with siRNA targeting 
E2F1, E2F3, or E2F5 significantly reduced the expression of MMP9 and MMP14 
mRNA as seen by quantitative RT-PCR, whereas E2F2 and E2F4 had no effect 
(Figure 11A).  Since we could not detect E2F5 on the MMP14 promoter with our 
chip assay of site -1657, it is possible that the regulation by E2F5 is through a 
different E2F binding site in the promoter. Surprisingly, MMP15 mRNA levels 
were not changed when E2Fs were depleted in either A549 cells or H1650 cells 
(Figure 11B). DHFR mRNA levels were significantly reduced when E2F1 or E2F3 
were depleted, correlating with E2F1 and E2F3 preferentially binding to DHFR 
promoter in ChIP assays (Figure 10). This suggests that E2F1, E2F3, and E2F5 
are involved in transcriptional induction of MMP9 and MMP14 genes in NSCLC 
cells, but they may play a lesser role in regulating the endogenous MMP15 
promoter.  
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Figure 11. E2F depletion inhibits MMP gene transcription (A-B) Transiently transfecting 
100 pmol of E2F1, E2F3, and E2F5 siRNA reduced the expression of MMP9 and 
MMP14 mRNA in A549 and H1650, and there was no significant difference with E2F2 or 
E2F4 siRNA. DHFR mRNA levels were significantly reduced by E2F1 or E2F3 siRNA 
(P<0.05). MMP15 mRNA levels were not affected significantly in A549 or H1650 cells. 
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Depletion of E2Fs inhibits collagen degradation  
  Recent studies suggest that in certain tumor milieus, the ability of 
fibroblasts to actively degrade extracellular collagen is a climacteric step that 
allows cancer cells to escape the primary tumor site (465). Since we found that 
NSCLC cells depleted of E2F1, E2F3, or E2F5 had less MMP9 and MMP14, we 
next examined whether CCL-210 lung fibroblasts had an impaired ability to 
degrade type I collagen, when depleted of E2F1-5.  To this end, CCL-210 cells 
were transfected with siRNA to E2F1-5 or a non-targeting control RNA and 
plated on type I collagen. After four days, CCL-210 cells with depleted E2F1-5 
had less collagen degradation as indicated by Coomassie staining of the residual 
collagen, though the depletion of E2F1 or E2F3 had the most pronounced effect 
(Figure 12). To determine whether siRNA had any effect of proliferation of CCL-
210 cells, cells were counted after being trypsinized off the collagen. There was 
no significant difference in cell number with any siRNA suggesting that CCL-210 
cells grown to confluency are not dependent of proliferation for collagen 
degradation. Taken together, these results suggest that depletion of E2Fs in lung 
cells significantly diminishes MMP gene transcription, and hinders resultant 
biological processes such as collagen degradation.  
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Figure 12. E2F depletion inhibits collagen degradation. CCL-210 lung fibroblast cells 
depleted of E2F1-5 by siRNA have less collagen degradation compared to Control 
siRNA. The results of three independent experiments are shown. The total cell number 
on top of collagen was trypsinized, and counted at the termination of the experiment. 
Depletion of E2F1-5 had no effect on growth of CCL-210 cells when plated as a 
confluent monolayer. Images are one representative field of CCL-210 cells atop 
collagen, taken at 100x total magnification with phase contrast microscopy. 
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E2F1 overexpression can rescue MMP-luciferase activity when E2F3 is 
depleted 
 
  To determine whether an alternate E2F family member could rescue MMP 
activity when E2F1 is depleted, A549 cells were transiently transfected with 
siRNA targeting E2F1, then transfected with MMP-luc constructs, with or without 
E2F3 expression vector. E2F1 depletion lead to reduced MMP9 and MMP14-luc 
activity, and overexpression of E2F3 could rescue MMP9 and MMP14-luciferase 
activity. Similar results were obtained when E2F3 was depleted, followed by 
overexpression of E2F1. MMP15-luciferase activity was not affected by E2F1 or 
E2F3 depletion (Figure 13). This suggests that E2Fs might have functional 
redundancy in regulating MMP promoters.  
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Figure 13. E2Fs can rescue the effect of depleting a different family member. MMP9 
and MMP14 luciferase activity is reduced by transiently transfecting E2F1 or E2F3 
siRNA, followed by transfection of MMP-luc reporters. Co-transfection with the alternate 
family member (E2F1 overexpression in E2F3 siRNA cells, E2F3 overexpression in 
E2F1 siRNA cells) could rescue MMP-luciferase activity. Basal levels of MMP15 were 
not affected, though both E2F1 and E2F3 overexpression could induce MMP15-
luciferase activity (*P<0.05). 
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Depletion of E2F1 or E2F3 reduces cell migration independent of 
proliferation 
 
 There is evidence that cell migration is accomplished in part through 
cleavage of adherens junctions by MMPs (311). To determine whether E2F-
mediated modulation of MMP genes might affect migration of A549 cells, wound-
healing assays were conducted in vitro. To ensure that changes in migration 
were independent of cell proliferation, asynchronous cells were pretreated with 
10 µg/mL Mitomycin C, which arrests the cell cycle (Figure 14A).  There was a 
comparable amount of migration in Mitomycin C treated and untreated cells, 
indicating that the observed migration was a direct result of motility into the 
empty space and independent of proliferation (Figure 14B-C). Next, to determine 
whether E2F depletion affected migration, cells were transfected with siRNA to 
E2F1, E2F3, a combination thereof, or a non-targeting control siRNA. Serum 
induced migration of cells transfected with the control, non-targeting siRNA into 
the wound; but migration was significantly reduced in cells transfected with E2F1 
and E2F3 siRNA (Figure 14D-E). This suggests that E2F1 and E2F3 contribute 
to the migration of cells. This agrees with studies showing that E2F1(-/-) mice 
have abnormal epidermal repair upon injury, and impaired cutaneous wound 
healing (466). 
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Figure 14. Depletion of E2F1 or E2F3 inhibits migration independent of proliferation (A) 
A549 cells that have been treated with 10 µg/mL Mitomycin C have significantly reduced 
BrdU incorporation compared to untreated A549 cells (*P<0.05). (B) Serum stimulated 
A549 cells treated with 10 µg/mL Mitomycin C have similar migratory capacity as 
untreated A549 cells (**P<0.005) 100x total magnification. (D) Depletion of E2F1, E2F3, 
or E2F1 and E2F3 combined significantly hinders the ability to A549 cells to migrate in 
response to serum (**P<0.005; ***P<0.001).  
B 
C 
D 
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Depletion of E2F1 or E2F3 reduces cell invasion 
 
We next examined whether invasion was affected by depletion of E2F1 or 
E2F3 using a Boyden Chamber assay.  A549 cells were transfected with siRNA 
targeting E2F1, E2F3 or a combination thereof. As shown in Figure 15A, cells 
which were depleted of E2F1 or E2F3 had completely lost the ability to invade 
through collagen and matrigel coated transwell filters, while cells transfected with 
a non-targeting control siRNA showed 1.8 ± 0.4 fold invasion in serum stimulated 
cells. This suggests that E2F1 or E2F3 are required for degradation of the ECM 
components, through the modulation of genes involved in their degradation.  
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Figure 15.  Depletion of E2F1 or E2F3 inhibits invasion (A) Depletion of E2Fs 
significantly reduced invasive properties, as seen in a Boyden Chamber assay 
(***P<0.001). Images of films removed from transwell filters. Dark spots are cells that 
have invaded through matrigel and collagen coated films to the other side of the filter. 
Images are taken at 400X total magnification. (B) Quantification of five images in three 
independent experiments. Data is plotted as fold change compared to serum-starved 
controls.  
A 
B 
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Rb-Raf-1 disruptor, RRD-251, inhibits invasion and migration in vitro 
 
Previous work in our lab has demonstrated that the Raf-1 kinase interacts 
with Rb, and phosphorylates Rb early in the cell cycle (36). A small molecule Rb-
Raf-1 disruptor, RRD-251, inhibited Rb phosphorylation, thereby keeping Rb 
associated with E2F1, preventing cell proliferation and tumor growth (38, 39). We 
hypothesized that RRD-251 would likely inhibit the migration of cancer cells as 
well, given that depletion of E2Fs inhibited migration. Wound healing assays 
conducted on MDA-MB-231, MDA-MB-435, A549, and H1650 cells showed that 
treatment with RRD-251 significantly reduced the migration of cells (Figure 16A). 
The ability of RRD-251 to inhibit invasion of cancer cells was also examined. 
Given that the depletion of E2F1, E2F3, or the combination of the two 
significantly inhibited invasion, we wanted to use RRD-251 to inhibit invasion in 
vitro. A549-luc-C8 cells were rendered quiescent by serum starvation for 24 
hours, and then stimulated with either serum alone, or serum and RRD-251 for 
18 hours and invasion was measured by a Boyden Chamber assay. It was found 
that RRD-251 could significantly abrogate the invasive capacity of A549-luc and 
MDA-MB-231 cells (Fig. 16B-C). 
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Figure 16. RRD-251 inhibits migration and invasion in vitro (A) MDA-MB-231, MDA-MB-
435, A549, and H1650 cells treated with RRD-251 show reduced migration compared to 
serum. (B-C) A549-luc-C8 and MDA-MB-231 cells have significantly more invasion when 
stimulated with serum (**P<0.005). This effect is significantly abrogated in both cell lines 
when treated with RRD-251 (A549-luc, ***P<0.001; MDA-MB-231, **P<0.005).  
A 
B C 
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Rb-Raf-1 disruptor, RRD-251, inhibits MMP transcription and collagen 
degradation 
  Since RRD-251 was effective at inhibiting migration and invasion in a 
panel of invasive cancer cell lines, we next tested the ability of RRD-251 to inhibit 
collagen degradation. Similarly, collagen degradation was also greatly inhibited 
after CCL-210 cells were treated with RRD-251 (Figure 17A). Given that 
invasion, migration, and collagen degradation were all inhibited by RRD-251, we 
hypothesized that the mechanism was likely due to a down-regulation of key 
MMP gene transcription. By blocking the Rb-Raf-1 interaction, Rb remains 
hypophosphorylated and active, thereby inhibiting E2F-mediated transcription of 
target genes. To determine if RRD-251 could prevent E2F-mediated transcription 
of MMP genes, quiescent A549 cells were serum stimulated in the presence or 
absence of 20 µM RRD-251. MMP mRNA levels decreased significantly after 
treatment with RRD-251 (Figure 17B), comparable to the reduction in expression 
when E2Fs were depleted. Collectively, these results suggest that RRD-251 
inhibits the invasion and migration of cancer cells, and this correlates with the 
repression of MMP genes.  Taken with previous studies showing the efficacy of 
RRD-251 at inhibiting human tumor xenograft growth, cell proliferation, and 
angiogenesis (39), the Rb-Raf-1 interaction seems to play a crucial role in many 
aspects of cancer development and progression.  
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Figure 17. RRD-251 inhibits transcription of MMPs and collagen degradation (B) CCL-
210 cells treated with RRD-251 show reduced degradation of collagen. Images show 
three independent experiments. (C) A549 cells treated with RRD-251 have significantly 
reduced MMP9, MMP14, and MMP15 mRNA (*P<0.05).  
A 
B 
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RRD-251 inhibits metastatic lung colonization in vivo 
 
  Given that RRD-251 could modulate MMP levels and inhibit 
invasion and migration in vitro, we next investigated if RRD-251 could inhibit 
metastasis in vivo. We injected A549-luc-C8 cells (5x106) into the lateral tail vein 
of 5-week-old female, SCID-beige mice.  Mice were then randomized into either 
the DMSO vehicle group, or the RRD-251 group, which received i.p. injection of 
50 mg/kg everyday for four weeks. Colonization of lungs was monitored using the 
Caliper-IVIS 200 system after administration of luciferin. Mice treated with RRD-
251 had significantly less metastasis to the lung and surrounding tissues (Figure 
18A-B). Photon Flux in vehicle treated mice was 3.9 ± 0.6 fold higher than mice 
treated with RRD-251. To confirm these observations seen in vivo, lung 
bioluminescence was examined ex vivo. Mice treated with RRD-251 had 80% 
less lung bioluminescence (Fig 18C-D), indicating less metastasis. H&E staining 
indicates that few tumors were able to seed in the lungs of mice treated with 
RRD-251 (Fig. 18E-F). It is difficult to differentiate between anti-proliferative 
effects and anti-metastastic effects, however, as proliferation also contributes to 
the growth of metastatic lesions.  Ideally, drugs that can affect invasion and 
proliferation would have the highest benefit as anti-tumor agents. RRD-251, by 
its ability to inhibit these hallmarks of cancer and others, appears to have potent 
therapeutic efficacy in vivo.  
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Figure 18. RRD-251 inhibits lung metastasis in vivo (A) A549-luc-C8 cells were injected 
into the lateral tail vein of SCID-beige mice, and animals were imaged once/week for 5 
weeks. Daily administration of 50mg/kg RRD-251 significantly reduced lung colonization 
(*P<0.05). Representative images are shown in (B). (C and D) At the completion of the 
experiment, lungs were analyzed ex vivo and extent of colonization quantified. Mice 
treated with RRD-251 had significantly less tumor burden (*P=0.015). (E and F) H & E 
staining confirms the presence of numerous distinct metastatic colony formation in the 
lungs of vehicle treated mice, shown by arrows, but few in mice treated with RRD-251.  
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Discussion 
 
  It is well established that cyclin-dependent kinases phosphorylate and 
inactivate Rb in the G1 phase of the cell cycle, releasing E2F transcription factors 
from Rb (467). It was initially believed that the predominant function of E2Fs was 
to activate genes required for the progression of the cell cycle through S-phase 
(8, 468, 469). Later studies showed that E2F transcription factors could regulate 
a diverse number of biological processes including cell differentiation, 
development, apoptosis, DNA damage repair, and more recently, angiogenesis 
(122, 175, 177, 470, 471). As mentioned earlier, our lab had shown that the 
signaling kinase Raf-1 directly interacts with Rb early in the cell cycle; further, 
Raf-1 could phosphorylate Rb (36). This phosphorylation of Rb by Raf-1 was 
necessary for the subsequent complete inactivation of Rb by cyclin-dependent 
kinases. Disrupting the Rb-Raf-1 interaction using RRD-251 could inhibit cell 
proliferation, adherence independent growth, angiogenesis and prevent the 
growth of lung cancer and melanomas in xenograft models (463). Studies 
presented here show that disrupting the Rb-Raf-1 interaction could be a fruitful 
way of combating metastatic colonization by cancer cells at distant organ sites; 
this can likely be attributed to downregulation of MMP transcription in addition to 
inhibition of proliferation.  Therefore, inhibiting the Rb-Raf-1 interaction might be 
a valid target for metastasis of primary tumors of any size, since there is no direct 
correlation between the size and metastatic potential.  
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  A considerable amount of research has been dedicated to identifying 
novel E2F regulated genes by gene profiling arrays and chromatin 
immunoprecipitation arrays (ChIP on chip) (127, 472-474). In these arrays, 
various proteins and enzymes involved in the metastatic spread of tumor cells 
were initial hits, though validation studies have been lacking. Arguably the most 
crucial process for cancer cell invasion is the physical degradation of the ECM 
(440) but a role for E2F transcription factors in this process had not been 
identified. It is intriguing that, at least in lung cancer cell lines, E2Fs function as 
transcriptional activators of MMP9, MMP14, and MMP15. Many MMP gene 
promoters have multiple GC boxes, which can bind to Sp1 and Sp3, including 
MMP9, MMP14, MMP15, and others (441). It is well established that Sp1 
proteins can work coordinately with E2F transcription factors to regulate gene 
expression (475). 
 
  Cells utilize enzymes including serine-, thiol-, proteinases, heparanases, 
and metalloproteinases to free them from the primary tumor locale. Though the 
activity of matrix metalloproteinases and other metzincin family proteins are 
important for metastasis, the most prognostically valuable are the Matrix 
Metalloproteinase family (MMPs) (476). A relevant MMP signature is MMP2, 
MMP9, and MMP14, which have been shown to correlate with advanced stage 
breast cancer morbidity and late relapse in breast cancer patients (477, 478). 
MMP14 and MMP2 have also been detected at high levels in NSCLC patient 
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samples, whereas MMP14 and MMP15 RNA levels have been shown to 
correlate with human glioma grade (479, 480). Therefore, it is a possibility that 
E2Fs might indirectly regulate tumor metastasis as a consequence of 
transcriptionally activating MMPs. 
 
  In addition to the crucial role for MMPs in degrading the extracellular 
matrix during invasion, they also play a role in angiogenesis. Pro-angiogenic 
factors like VEGF and bFGF are normally localized to the matrix, and cannot 
engage receptors until freed through MMP9 cleavage (434, 481, 482). Since we 
have previously shown that VEGF receptors, FLT-1 and KDR, are also E2F 
regulated genes, it is likely that the role E2F has in angiogenesis is multi-faceted.  
 
  These observations raise the possibility that mutations that initiate the 
oncogenic process by activating the E2F transcriptional regulatory pathway might 
also contribute to subsequent steps of tumor progression and metastasis. There 
is evidence that the Rb-E2F pathway might affect EMT as well, and this requires 
additional investigation (483). Taken together, these studies link the Rb-E2F cell 
cycle regulatory pathway to advanced stages of cancer development and 
metastasis. The finding that disrupting the Rb-Raf-1 interaction could prevent cell 
proliferation, angiogenesis, tumor growth and now metastatic colonization of 
organs suggest that targeting the Rb-R2F pathway might be a fruitful avenue to 
combat metastatic disease.  
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Chapter 4: Differential regulation of MMP2 by E2F1 involves a p53-KAP1-
HDAC1-dependent mechanism 
 
Abstract 
Recent studies have shown a role for the Rb-E2F pathway in regulation of 
certain matrix metalloproteinase genes involved in tumor invasion and 
metastasis. Another MMP implicated in migration and invasion, MMP2, has 
multiple E2F binding sites in its gene promoter and is differentially regulated by 
the Rb-E2F pathway in lung cancer and breast cancer cell lines. Chromatin 
immunoprecipitation assays showed the association of Rb and E2F1-5 with the 
MMP2 promoter, and transient transfection experiments showed that MMP2-
luciferase construct is repressed by E2F1-5, and further by Rb, in NSCLC cells. 
In contrast the MMP2-luc construct was induced by E2F1-5 in breast cancer 
cells. Correspondingly, depletion of E2F family members by siRNA transfection 
induced MMP2 transcription in NSCLC cell lines. Using a candidate approach, 
we screened a panel of siRNAs targeting known transcriptional repressors and 
cooperative transcription factors that had putative binding sites in the MMP2 
promoter. This identified c-MYC and ID1 as potential mediators of E2F-mediated 
repression, though there was no effect when Rb, BRG1, or other known 
repressors were depleted. Deletion mutants of the MMP2 promoter revealed a 
49-base pair region (-1649/-1600) required for E2F-mediated repression in 
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NSCLC cells. This region contains a consensus p53-binding site that is known to 
regulate MMP2 expression, in addition to an E2F binding site. Mutation analysis 
showed that the p53 binding site and the E2F binding site are required for E2F-
mediated repression of MMP2, and the c-MYC binding element was dispensable 
for E2F-mediated repression, suggesting that the effects of c-MYC and ID1 are 
through an indirect mechanism. Further, KAP1 and HDAC1 could significantly 
inhibit p53-mediated transactivation of MMP2, and depletion of KAP1 prevented 
E2F1-mediated repression in NSCLC cells. Overexpression of p300 histone 
acetyltransferase could rescue E2F-mediated repression, suggesting that 
deacetylation of E2F1 or histones in the promoter region contribute to repression. 
In breast cancer cells, the mechanism for E2F inducing MMP2 activity is due to a 
mutation in p53, or low levels of HDAC-KAP1 binding as seen by 
immunoprecipitation immunoblot, or double immunofluorescence studies. Taken 
together, E2F1 represses MMP2 expression in NSCLC cells through p53-KAP1-
HDAC1-mediated deacetylation event, whereas c-MYC and ID1 regulate MMP2 
through an unknown, indirect mechanism.  
 
Introduction 
  The retinoblastoma tumor suppressor protein, Rb, together with the E2F 
transcription factors are critical regulators of the cell cycle, apoptosis cascades, 
differentiation, and DNA damage repair for normal cells and cancer cells alike 
(53, 66, 449). In cancer, the Rb-E2F pathway is frequently altered (12). While Rb 
is mutated in retinoblastoma, breast cancers, lung cancers, osteosarcomas and 
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other cancers, numerous aberrations including overexpression, amplification, and 
mutations of the E2F family members themselves are being discovered (12, 66, 
461, 462). Recent studies found that the Raf-1-Rb-E2F signaling cascade could 
directly regulate the expression of key angiogenesis and metastasis genes such 
as FLT-1, KDR, Angiopoiten-2, MMP9, MMP14, and to a lesser extent MMP15, 
linking early stage oncogenic events elicited by this pathway to later stage events 
in cancer, namely metastasis (253, 448). In addition, the Rb-Raf-1 disruptor, 
RRD-251, which prevents Rb phosphorylation and inhibits E2F1-mediated 
transcription, inhibited metastasis in an in vivo experimental metastasis model, 
and down-regulated the transcription of crucial MMP genes. RRD-251 inhibited 
invasion, migration, and collagen degradation in a proliferation-independent 
manner in vitro (448). However, the precise mechanism for the emergence of 
disseminated metastases in patients is still poorly understood—despite being the 
primary cause of mortality (266, 327). 
  
  The matrix metalloproteinases, or MMPs, are a family of 23 enzymes in 
humans that can collectively degrade all components of the extracellular matrix 
(374).  A hallmark of invading tumor cells is their ability to degrade the 
surrounding ECM, leading to tissue pore development that can aid in the escape 
from the primary tumor. With most cancers, invasion is associated with an 
increase in MMP activity (476). Most tumors and subsequently derived cell lines 
express the type IV collagenases MMP2 and MMP9 at normal to high levels 
(431). In gliomas MMP2 and MMP9 had highest expression in high-grade 
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gliomas compared for low-grade astroglimoas and normal brain (484). Increased 
expression of MMP2 in non-small cell lung cancer was associated with increased 
tumor recurrence (p=0.001), decreased overall survival (p=0.0004), and 
advanced stage disease (p=0.001) (485). Immunohistochemical analysis of 
human non-small cell lung cancer samples also revealed that MMP2 levels 
correlated with advanced tumor stage and the presence of distant metastasis 
(p<0.05) (486).  Another study showed that strong staining of MMP2 and MMP9 
in the stromal cell compartment of NSCLC, particularly in fibroblasts could also 
correlate with an increase in microvessel density, angiogenesis, and poor 
prognosis (487). MMP2 was identified as part of a gene signature that imparted 
breast cancer cells the ability to metastasize to the lung, (343). MMP2 was also 
involved in the assembly of new tumor blood vessels, the release of tumor cells 
into circulation, and tumor cell seeding into the pulmonary vasculature when 
overexpressed with MMP1, COX2, and epiregulin (488).  
  
  The activity of MMP2 is regulated at a variety of levels: these include 
transcriptional, proenzyme activation by tissue inhibitor of metalloproteinase-2 
and membrane-type metalloproteinase complexes, and inhibition of catalytic 
activity by TIMPs (311, 489).  A search for promoter regions responsible for the 
upregulation of MMP2 in cancer has yielded a well-characterized promoter with a 
number of potential regulatory cis elements, including those responsible for the 
constitutive activation of MMP2—AP-1, Ets-1, C/EBP, CREB, PEA3, Sp1, and 
AP-2 (489). Other studies have suggested that AP-2 can bind to a non-canonical 
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enhancer region at -1635 (490), while other groups have shown that p53 can 
bind to a 20 base pair sequence from -1649 to -1630, also in the enhancer 
region, and directly regulate the expression of MMP2 (491). The nature of 
constitutive expression of MMP2 versus expression during metastasis is unclear. 
Given that E2Fs are deregulated or overexpressed in various cancers, and they 
are responsible for regulation of other MMP genes, we performed studies to 
determine if MMP2 was also regulated by E2Fs in both NSCLC cell lines, and 
breast cancer cell lines. Surprisingly, the MMP2 promoter is repressed by E2Fs 
in NSCLC cell lines by cooperative activity with the adjacent p53 binding site. 
Together, E2F and p53 can tether a KAP1-HDAC1 complex to the promoter, 
effectively shutting down transcription. The MMP2 promoter can also be 
repressed by c-MYC in the same region, though independent of c-MYC binding; 
this repression is relieved by ID1, possibly through direct de-repression by the 
helix-loop-helix protein. In breast cancer cells, however, E2F1 is an activator of 
the MMP2 promoter, where the mechanism for activation is either from a lack of 
KAP1-HDAC interaction (MCF7 cells) or mutant p53 status (MDA-MB-231 cells). 
In this scenario, E2F1 binding does not recruit a repressive complex, as not all 
components are available.  Taken together, the MMP2 gene is also a 
transcriptional target of the Rb-E2F pathway, and can be either activated or 
repressed depending on additional aberrations in the genetic landscape of the 
tumor.   
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Results 
MMP2 promoter is transcriptionally regulated by E2F transcription factors 
  MMP2 is upregulated in a variety of metastatic cancers, and MMP9, 
MMP14, and MMP15 are E2F target genes (448). To determine if MMP2 is also 
an E2F target gene, we examined the promoter region 2 Kb upstream of the 
transcriptional start site using the Matinspector (Genomatix) program. In this 
region there were four putative E2F binding sites at -1616, -1077, -914, and -256.  
To determine if these binding sites were functional, a ChIP assay was conducted 
on asynchronously growing A549 cells. Antibodies against Rb, and E2F1-5 
showed a significant amount of protein binding to chromatin (Figure 19A-B). 
There was no DNA associated with an IP done with an irrelevant antibody, 
further establishing the specificity of the assay. This suggested that there is at 
least one functional element in the promoter that can actively recruit E2F family 
members and Rb.  
   
  Since E2Fs were recruited to the MMP2 promoter, we next examined if 
E2Fs could regulate the expression of the endogenous gene. Towards this 
purpose, A549, H1650, H1975, and CCL-210 cells, all derived from the lung, 
were transfected with 100 pmol of siRNA targeting E2F1, E2F3, or a non-
targeting control siRNA. Surprisingly, in all four cell lines, depletion of E2F1 or 
E2F3 induced the MMP2 mRNA levels as indicated by qRT-PCR (Figure 19C). 
This suggests that E2Fs might be acting as repressors of MMP2 expression in 
lung cancer cell lines.   
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  To further study regulation of the MMP2 promoter by E2Fs, we utilized an 
exogenous MMP2-luciferase reporter construct. When cotransfected with E2F1 
or E2F3, the MMP2 promoter was indeed repressed (Figure 19D). Further, 
cotransfection with the Rb construct could repress the MMP2 promoter even 
more. We next asked if E2Fs 1-5 behaved similarly when overexpressed along 
with the MMP2-luciferase construct. All E2F family members significantly repress 
MMP2 In H1650 and A549 cells. Contrastingly, when MCF7 or MDA-MB-231 
breast cancer cells are cotransfected with the MMP2-luciferase construct and 
E2F 1-5, MMP2-luc is induced (Figure 19E-F). This is intriguing given that MMP2 
levels were dramatically increased in a breast cancer to lung metastasis model 
(343) and that E2F activity can also be increased in breast cancer through 
mutation of Rb. 
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Figure 19. MMP2 is transcriptionally regulated by the Rb-E2F pathway (A) Table of 
putative E2F binding elements identified by Matinspector (Genomatix). (B) ChIP assay 
conducted on asynchronously growing A549 cells using the indicated antibodies. 
Sonicated genomic DNA was used for input. Primers span the -1616 to -1600 site.  (C) 
Transiently transfecting 100 pmol of E2F1 or E2F3 siRNA increased the expression of 
MMP2 in four lung cancer cell lines. (D) Transient tranfections in A549 cells showed that 
E2F1 and E2F3 could repress MMP2-luciferase activity, and further repression was 
observed with the addition of Rb. (E-F) In A549 and H1650 cells, E2F1-E2F5 could 
repress the MMP2-promoter, whereas E2F1-E2F5 activated the MMP2 construct in 
breast cancer cell lines. 
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E2F represses MMP2 independent of Rb, BRG1 or other known 
corepressors 
  Different types of E2F complexes are capable of inhibiting transcription of 
target genes. For example, in quiescent cells, E2F4 and E2F5 preferentially bind 
to Rb family members p107 and p130, and recruit a variety of chromatin 
modifiers to efficiently shut down transcription (8). Further, the E2F activators 
have been observed repressing promoters directly in vivo as well through an 
unknown mechanism (177). Since we also observed E2F1-5 could repress 
exogenous MMP2 promoter when transfected into lung cancer cells, we first 
explored the role of Rb.  To this end, we transfected MMP2-luc alone, or MMP2-
luc with E2F1 or E2F3 into cells that were stably transfected with shRNA 
targeting Rb, or a non-targeting control (39), (Figure 20A). In both cases, MMP2-
luc was repressed by the E2F transcription factors. This shows that although Rb 
could repress MMP2-luc when overexpressed (Figure 19D), it was not essential 
for repression. We next asked whether BRG1, a known repressor of E2F 
proliferative genes (39), would also repress the MMP2 promoter through E2F. 
We found that BRG1 overexpression is slightly activating, and had no affect on 
E2F-mediated repression (Figure 20B). We next tested a panel of known E2F 
transcriptional repressors by first transfecting siRNA targeting HP1γ (492), β-
arrestin1 (48), LSD-1, Prohibitin-1 (PHB-1) (492), YY1 (493), BRG1 (39), or 
Sin3a (494), followed by transfection with the MMP2-luc construct alone, or with 
E2F1 (Figure 20C). In all cases, E2F1 represses MMP2-luc compared to MMP2-
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luc control. Interestingly, BRG1 and Sin3a depletion results in less MMP2 
luciferase activity, suggesting they are required for basal expression of MMP2.   
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Figure 20. E2F1 represses MMP2 independent of Rb, BRG1, or other known 
corepressors (A) A549 cells under puromycin selection to retain the shRNA vector 
targeting Rb, or a non-targeting control vector were transiently transfected with MMP2-
luc alone, or with E2F1 or E2F3. Rb was not required for E2F-mediated repression.  (B) 
A549 cells were transfected with MMP2-luc alone,  or with E2F1, BRG1, or a 
combination of both. Although BRG1 activated the MMP2 promoter slightly, E2F still 
repressed MMP2-luc. (C) A549 cells were first transfected with 100 pmol of siRNA 
targeting indicated transcripts, followed by transfection with MMP2-luc alone, or with 
E2F1. The loss of each corepressor had no effect on E2F-mediated repression of 
MMP2.  
A B 
C 
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c-MYC and ID1 depletion enhances MMP2-luciferase activity 
  Since the depletion of various corepressor proteins had no effect on E2F-
mediated repression of MMP2, we next hypothesized that E2F could be 
repressing the MMP2 promoter cooperatively with another transcription factor. 
Previous studies had already identified several regulatory elements in the MMP2 
promoter, including AP-1, AP-2α, Sp1, PEA3, Ets-1, and CREB (489). We also 
chose to examine the effects of ID1 and c-MYC. Both proteins can act as either 
activators (346, 495) or repressors (496, 497) depending on promoter context, 
and both have been shown to play a role in regulating metastasis (346, 498).  
Firstly, A549 cells were transfected with an siRNA targeting either AP-2α, ID1, 
Sp1, c-MYC, ETS1 or a non-targeting control siRNA, followed by the MMP2-luc 
construct with or without E2F1. When Sp1 was depleted, there was slightly less 
basal promoter activity, consistent with previous reports done on gliomas cells 
(489). However when AP-2α, ID1, c-MYC or ETS1 were depleted, the basal 
levels of MMP2-luc were increased to varying degrees (Figure 21). Depletion of 
ID1 induced MMP2-luc around 3-fold. Further, with E2F1 was cotransfected, 
though still repressing MMP2-luc, the repression was reduced. This suggests 
that ID1 might contribute to E2F-mediated repression. Similar results were 
observed in the case of c-MYC. Depletion of c-MYC increases MMP2-luc levels 
as well, and the effects of E2F1 are much less pronounced.  
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Figure 21.  ID1 and c-MYC depletion inhibits E2F-mediated repression of MMP2-
luciferase. A549 cells were first transfected with 100 pmol of siRNA targeting indicated 
transcripts, followed by transfection with MMP2-luc alone, or with E2F1. The loss of Sp1 
resulted in a slightly reduced basal MMP2-luc activity, though the addition of E2F1 could 
repress even further. Although AP2α, ID1, c-MYC, and ETS1 depletion increased the 
basal level of MMP2-luc activity, only the loss of ID1 and c-MYC had any affect on E2F-
mediated repression.   
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c-MYC directly binds and colocalizes with ID1 
 It has previously been reported that c-Myc can induce ID1, ID2, and ID3 
(499-501). However it is also possible that since both ID proteins and c-MYC are 
helix-loop helix proteins, they could also function through direct physical binding. 
In this scenario, ID1 would bind to c-MYC, and free c-MYC from DNA. To 
determine whether ID1 and c-MYC can colocalize in the cell, we utilized double 
immunofluorescence experiments. Asynchronous A549, H1650, and MDA-MB-
231 cells were immunostained with ID1 and c-MYC to observe a direct 
interaction. In both lung cancer cell lines, A549 and H1650, there is a strong 
colocalization between ID1 and c-MYC (Figure 22A), whereas in MDA-MB-231 
cells there is less colocalization. Upon quantification of the immunofluorescence 
of both ID1 and c-MYC, it was confirmed that MDA-MB-231 cells had the lowest 
levels of ID1-associated immunofluorescence (Figure 22B). To confirm these 
observations, we performed immunoprecipitation and immunoblot analysis on the 
three cell lines. In all cell lines, there was detectable interaction between 
endogenous c-MYC and ID1 (Figure 22C). This binding should result in less c-
MYC associated with the MMP2-promoter, and if c-MYC is in fact a repressor, 
this release would yield more MMP2-luc activity. Together these results suggest 
that in addition to c-MYC transcriptionally regulating ID1, there might be a 
negative feedback loop, at least at the exogenous MMP2-luc promoter, where 
ID1 can bind to c-MYC. 
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Figure 22. c-MYC directly binds to ID1 in lung cancer cells. (A) Serum-starved A549 and 
localization of c-MYC and ID1 was analyzed by double-immunofluorescence staining 
followed by confocal microscopy. The cells were counterstained with the nuclear marker, 
4′6-diamidino-2-phenylindole (DAPI). Overlay of the images show yellow spots indicating 
colocalization in the far right panel. (B) Both channels of immunofluorescence were 
quantified. (C) The physical interaction of endogenous c-MYC and ID1 was confirmed by 
immunoprecipitation of ID1 followed by immunoblot analysis. 
A 
B C 
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Identification of the promoter region responsible for E2F and c-MYC 
mediated repression of MMP2-luciferase 
 Given that Matinspector can generate hundreds of possible regulatory 
elements for any given DNA sequence, experiments were done to first determine 
the region of DNA responsible for E2F-mediated repression in the MMP2 
promoter.  We generated 5’ deletion mutants from the original wild type -1659 
base pair MMP2-reporter construct (489, 491) including -1467, -945, -508, -221. 
Each deletion was created to eliminate one putative E2F binding site per 
mutation (Figure 23A). Each of these constructs was transiently transfected 
alone, or with E2F1 in both A549 and H1650 cell lines. All data was normalized 
to the full-length -1659 base pair promoter alone.  The relative luciferase activity 
from the first deletion mutant (-1467) was increased compared to the full length (-
1659) and E2F1 no longer could repress the transcription of MMP2-luc, but was 
activating instead (Figure 23A). The RLA of the remaining luciferase constructs 
was comparable to the first deletion construct (-1467). Interestingly, the sole c-
MYC binding element identified in Matinspector was not in the DNA region 
required for E2F-mediated repression, although this region does have the 
previously characterized p53 binding site (491). To further study this region of the 
promoter, we transiently transfected A549 cells with the -1659 or -1467 promoter 
along with E2F1, c-MYC, p53, or the combination of E2F1 with p53, or c-MYC 
with p53 (Figure 23B). In agreement with prior studies (491), p53 was 
transcriptionally activating the MMP2 promoter when transfected alone, although 
cotransfection with either c-MYC or E2F1 resulted in repression of the -1659 
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MMP2 promoter. This suggests that both E2F and c-MYC could repress p53-
mediated transactivation of the MMP2-promoter.  In the shorter fragment, E2F1, 
c-MYC and p53 were all slightly activating, and there was no effect when p53 
was cotransfected with either E2F1 or c-MYC. It is possible that E2F1 and c-
MYC can bind additional putative sites, and the effects seen with p53 in the 
smaller fragment could be indirect; p53 may be upregulating an unknown gene 
that results in upregulation of MMP2-luciferase.   
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Figure 23. Identification of a repressor region in the MMP2 promoter (A) A549 and 
H1650 cells were transfected with deletion mutants of MMP2-luc alone, or with E2F1. 
The first deletion mutation increased RLA, and completely abolished E2F1-mediated 
repression. (B) A549 cells were transfected with the full-length -1659-luc construct or the 
-1467-luc construct along with E2F1, c-MYC, p53, or indicated combinations. Both E2F1 
and c-MYC inhibited the p53-mediated activation of MMP2-luc in the full-length 
construct, but not in the mutant construct.  
A 
B 
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Contribution of the p53, E2F, and c-MYC binding sites for the activity of the 
MMP2 promoter 
 Given that the MMP2 promoter was repressed by E2F1 through the region 
between -1659 and -1467, and that MMP2 RLA was induced by p53, we next 
tested the requirement of the individual binding sites to mediate these effects. 
We created promoter constructs with either a mutated p53, E2F or c-MYC 
binding site using overlap-extension PCR, as described in materials and methods 
(Figure 24 and 25A). We also created an additional deletion mutation yielding a  
-1617 construct that lacks the p53 binding element, but still has the E2F binding 
element intact.  When transfected into A549 cells, the MMP2-promoter construct 
harboring a mutation in the p53 binding site was no longer activated by p53 
(Figure 24B; lane 3 and lane 9). This mutation also resulted in E2F1 activating 
MMP2-luc, rather than repressing MMP2-luc. Similar results were observed when 
the -1617 deletion mutant was transfected (Figure 25B). Together, these data 
suggest that E2F1 requires the p53-binding site to repress the MMP2 promoter. 
Next, we tested the requirement of the E2F binding site between -1616 and -
1600. Using the -1659 MMP2-luc construct with a mutant E2F binding site, E2F1 
was no longer able to repress MMP2-luc (lane 2 with lane 11). Similar results 
were seen when transfections were done in MCF7 cells, however E2F1 activated 
the full length promoter (Figure 25C), consistent with the observation that lung 
cancer and breast cancer cells are differentially regulated. To further investigate 
the contribution of c-MYC, an MMP2-luc construct with a mutation in the c-MYC 
binding site was used. When transfected in H1650 cells, with two different 
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promoter clones, the mutation had no effect on c-MYC-mediated repression 
(Figure 25D); further suggesting that c-MYC plays an indirect role in regulation of 
the MMP2 promoter, or utilizes other cryptic sites on the promoter to repress 
MMP2.  
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Figure 24. Design of transcription factor binding site mutants. (A) The location of the 
predicted p53-binding site is underlined, and the core binding sequences are shown in a 
larger font. The nucleotides that were changed are highlighted with red font. This was 
confirmed by DNA sequencing. The E2F binding site uses the TTT sequence, and the 
conserved cytosine reside to mediate E2F binding. The indicated changes are in red. (B) 
The CA residues in the center of the c-MYC binding element were changed to GG. The 
indicated changes are in red font. 
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Figure 25. p53 and E2F1 binding sites contribute to MMP2 promoter activity. (A) 
Schematic representation of promoter constructs made. Red box with a star represents 
where mutations were created. (B-C) A549 and MCF7 cells were cotransfected  with 
MMP2-luc constructs with indicated mutations or deletions, along with E2F1 or p53. Both 
the p53 binding site and the E2F binding site were required for E2F-mediated repression 
of MMP2-luc in A549 cells, and the E2F site was essential for activation in MCF7 cells 
(D) H1650 cells were transfected with MMP2-luc constructs with a mutated c-MYC 
binding element. There was no effect when the c-MYC site was mutated.  
A B 
C D 
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A corepressor complex containing p53-KAP1-HDAC1 is responsible for 
E2F-mediated repression of MMP2 
 We next wanted to identify the mechanism that E2F employs to shut down 
p53-mediated activation. Previous studies have shown that nuclear corepressor 
KAP1 could repress p53 by interacting with MDM2, and recruiting HDAC1 to p53 
target genes. This results in the deacetylation of p53 protein (502). Another study 
demonstrated that KAP1 can also tether HDAC1 to E2F1, and similarly 
deacetylate the E2F1 protein (503). Since both of these proteins were 
cooperating to repress MMP2, we sought to determine whether KAP1 plays a 
role in repression. A549 cells were first transfected with siRNA targeting HDAC1, 
KAP1, or p53, followed by transfection with the -1659 MMP2-luc construct alone, 
or with E2F1. In all cases, depletion of these components resulted in less 
repression by E2F1 (Figure 26A). To further characterize the contribution of 
KAP1 in the repression of MMP2, we transfected A549 and H1650 cells with the 
MMP2-luc construct, along with E2F1, KAP1, p53, or combinations of the three. 
In A549 cells and H1650 cells, KAP1 inhibits p53-mediated activation when 
cotransfected (Figure 26B). To determine if the repression of transcription is due 
to KAP1-HDAC complex, we performed rescue experiments in both A549 and 
H1650 cells. In both cell lines, the histone acetyltransferase p300 could rescue 
E2F-mediated repression of MMP2 (Figure 26C). This suggests that the 
repressive role of KAP1 is probably through deacetylation.  
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Figure 26. A corepressor complex containing p53-E2F1-KAP1-HDAC1 is responsible for 
repression of MMP2. (A) A549 cells were transfected with 100 pmol of siRNA targeting 
HDAC1, KAP1, p53, or a non-targeting control, followed by transfection with MMP2-luc 
alone or with E2F1. Depletion of these transcripts abrogated E2F-mediated repression. 
(B) A549 and H1650 cells were transfected with MMP2-luc along with E2F1, KAP1, p53, 
or combinations. In both cell lines, KAP1 completely inhibited p53 activation of MMP2 
RLA. (C) A549 and H1650 cells were transfected with MMP2-luc along with E2F1, p300, 
KAP1, or combinations. p300 overexpression could rescue the E2F-mediated 
repression.  
A B 
C 
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KAP1 binding to HDAC1 is required for repression of MMP2 
E2F-mediated repression of MMP2-luc activity was only observed in lung 
cancer cells, whereas in breast cancer cell lines E2F was activating. MDA-MB-
231 cells express high levels of mutant p53 (504, 505), and mutant p53 can 
interfere with wild type p53 through several mechanisms, including acting as a 
dominant negative protein (506). Further, although mutant p53 is more stable 
than wild type p53 (507, 508), it can be recruited to different promoters than wild 
type, indicating that the DNA binding specificity might change (509, 510). This 
could explain why MDA-MB-231 can use E2F1 to activate MMP2-luc, since p53 
binding upstream is required for repression. Interestingly, MCF7 cells have wild 
type p53, though E2F1 can still activate the MMP2 promoter in this cell line.  To 
try to understand the mechanism for activation in these breast cancer cell lines, 
ChIP assays were conducted with antibodies against Rb, E2F1, HDAC1, p53, 
MDM2, KAP1, and irrelevant antibody was used as a negative IP control.  A549 
and H1650 cells recruited each protein to the MMP2 promoter (Figure 27A). As 
predicted, in MDA-MB-231 cells, there is no p53 recruitment. MCF7 cells 
recruited each protein except HDAC1. Since HDAC1 activity is required for 
repression of MMP2 by E2F1, we next performed immunoprecipitation 
immunoblots to determine the level of HDAC1-KAP1 binding in these four cell 
lines. A549, H1650, and MDA-MB-231 cells showed an interaction of 
endogenous HDAC1 with KAP1, while MCF7 cells showed no detectable 
interaction (Figure 27B-C). To confirm these observations, we utilized double 
immunofluorescence experiments to further visualize the endogenous interaction 
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between HDAC1 and KAP1 in the four cell lines. Asynchronous A549, H1650, 
MCF7 and MDA-MB-231 cells were immunostained with HDAC1 and KAP1 to 
observe a direct interaction, then subjected to confocal microscopy. 
Corresponding with the immunoprecipitation experiments, A549, H1650, and 
MDA-MB-231 cells show a strong colocalization between HDAC1 and KAP1 
(Figure 27D), whereas in MCF7 cells, there were high levels of KAP1, but low 
levels of colocalization with HDAC1. Therefore, two separate mechanisms can 
account for the activation of the MMP2-luciferase construct in breast cancer 
cells—MDA-MB-231 cells, which have mutant p53, cannot recruit the repressor 
complex, and MCF7 cells have insufficient KAP1 binding to HDAC1, which also 
results in activation of MMP2-luc.  
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Figure 27. KAP1-HDAC1 interaction is required for repression of MMP2.  (A) ChIP 
assays were performed on A549, H1650, MDA-MB-231, and MCF7 cell lines with 
indicated antibodies. There is no binding of p53 in MDA-MB-231 cells, and no binding of 
HDAC1 in MCF7 cells. (B-C) Immunoprecipitation of HDAC1 (B) or KAP1 (C) followed 
by immunoblotting with the other protein shows interaction of the endogenous proteins in 
A549, H1650, and MDA-MB-231 cells, but not MCF7 cells. (D) Double 
immunofluorescence confocal microscopy on A549, H1650, MDA-MB-231, and MCF7 
cells reveals that KAP1 does not colocalize with HDAC1 in MCF7 cells.  
A 
B C 
D 
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(±)-Nutlin-3, the p53-MDM2 disruptor, activates the MMP2 promoter 
(±)-Nutlin-3 is a small molecule inhibitor of the MDM2-p53 interaction, 
which leads to p53 stabilization, activation of cell cycle arrest and apoptosis 
(511). There are a number of clinical trials that employ the concept that selective 
p53 activation by (±)-Nutlin-3 might represent an alternative to current cytotoxic 
chemotherapy, in particular for pediatric tumors and hematological malignancies, 
which retain a high percentage of wild type p53 (512). Prior studies have also 
shown that MDM2 was required for KAP1 to recruit HDAC1 to p53, and mediate 
deacetylation (502). To determine the effects of (±)-Nutlin-3 on MMP2-luciferase 
activity, A549 and H1650 cells were transfected with the MMP2-luc construct, 
then treated with increasing amounts of (±)-Nutlin-3 for 24 hours. By blocking the 
p53-MDM2 interaction, and consequently inhibiting KAP1 recruitment of 
corepressor HDAC1, the MMP2-luc activity was de-repressed in a dose-
dependent manner (Figure 28A). To determine if these same effects could be 
observed on the endogenous MMP2 promoter, A549 cells were treated with (±)-
Nutlin-3 for 24 hours, then total RNA was collected and p53 target gene levels 
were analyzed by qRT-PCR. As predicted, p21 levels were increased and 
survivin levels were reduced, both representative of p53-dependent cell cycle 
arrest. MMP2 levels were also induced by treatment with (±)-Nutlin-3 (Figure 
28B), suggesting that blocking the MDM2-p53 interaction might result in a more 
metastatic phenotype for cancer cells, despite stabilization of p53.  
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Figure 28. The p53-MDM2 disruptor, (±)-Nutlin 3, activates the MMP2 promoter (A) 
A549 and H1650 cells treated with increasing concentrations of (±)-Nutlin 3 have 
increased MMP2 RLA. (B) Total RNA was collected from A549 cells treated with 10 µM 
(±)-Nutlin 3 for 24 hours. qRT-PCR data shows that (±)-Nutlin 3 treated cells had 
increased levels of MMP2 and p21, and decreased levels of survivin.  
A 
B 
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Discussion 
 The type IV collagenase, MMP2 or 72-kDa gelatinase A is one of the well-
studied family members in the large family of matrix metalloproteinases. The 
enzyme is secreted as an inactive zymogen, and it requires further processing for 
activation (513). This is usually achieved through proteolytic degradation. The 
main substrates for MMP2 include type IV collagen and fibronectins, both main 
components of the basement membrane, and it is overexpressed in a variety of 
pathological conditions, particularly in cancer (374, 514-516). MMP2 regulation is 
complex, being regulated on the transcriptional level, at level of zymogen 
processing, and binding to tissue inhibitors of metalloproteinases (TIMPs). In 
fact, the activation of MMP2 is largely dependent on TIMP2 tethering to the cell 
surface associated MMP14 (517-520). Further, MMP2 activity can be 
upregulated by a number of stimuli, including TGF-β1 (521), interferon, 
transfection of Ras (522) or nicotine stimulation (523).  
  
 When the MMP2 5’ upstream promoter region was cloned, it was 
demonstrated that wild type p53 was a transcriptional activator in HT1080 cells 
(491); however other groups found that in astroglioma cells the p53 response 
element was not required for constitutive activation of MMP2. This suggests that 
the regulatory mechanism of MMP2 is cell type dependent. Further, studies have 
demonstrated a role for ATF3 in antagonizing p53-dependent trans-activation of 
the MMP2 promoter through the DNA element of -1659 to -1622, the same 
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region that we have identified as important for E2F-mediated repression. In lung 
cancer cell lines, although ATF3 could antagonize p53, it was not required by 
E2F to mediate repression of MMP2 (data not shown).  Prior studies have utilized 
Matinspector (Genomatix) to identify potential mechanisms for the constitutive 
expression of MMP2, and found a number of cis-elements including AP1, ETS-1, 
C/EBP, CREB, PEA3, SP1, AP2, and a number of GC box regions assumed to 
be for SP transcription factors (489). Given that MMP2 can be induced by a 
number of stimuli in normal physiological processes or under pathological 
conditions, efforts were made to identify additional promoter response elements 
in the MMP2 promoter. Further sequence analysis has revealed that NFκB (441) 
and E2F transcription factors were putative regulatory elements in the MMP2 
promoter (448). 
 
 MMP2 deficient mice have reduced rates of tumor progression, 
highlighting a role for MMP2 in the advancement of cancer (412). Importantly 
there have been multiple studies aimed at using MMP2 as a biomarker for the 
advancement of disease. In non-small cell lung cancer, MMP2 expression in the 
stromal fibroblasts was shown to correlate with enhanced angiogenesis and poor 
prognosis (487) however other studies show that MMP2 expression has a limited 
informative value for NSCLC prognosis (524). Further, although MMP2 is 
transcriptionally silenced through an unknown mechanism or posttranscriptional 
inhibited in most breast cancer cells lines, multiple groups have demonstrated 
high levels of MMP2 RNA and protein in more advanced stages of breast cancer 
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(525-528). Animal models have also shown that MMP2 is an essential protease 
for metastasis of breast cancer to the lung (343) and brain (529). These 
observations compliment studies showing that E2F1 is overexpressed in human 
breast cancer (228).  
 
  Our studies show that by using 5’-deletion mutants of the MMP2 promoter 
that the p53 element contributes to activation of MMP2 in both breast and lung 
cancer cells. We show that in cells containing mutant p53, the MMP2 promoter is 
activated by E2F1, likely due to the mutant p53 protein being unable to bind the 
MMP2 promoter and aid in E2F-mediated repression. Other studies have also 
demonstrated that mutant p53 could not induce the MMP2 promoter, which is 
also the case with MDA-MB-231 cells (489, 491). In addition, we show that E2F1-
5 can physically bind, and inhibit the transactivation of MMP2 by p53 through a 
corepressor complex with KAP1 and HDAC1. Given that the depletion of HDAC1 
could only partially inhibit the repressive effects of E2F1, it is possible that other 
HDAC family members might be compensating for the loss of HDAC1. Further, 
KAP1 has been shown to physically recruit the Mi-2α subunit of the NuRD 
chromatin-remodeling complex (530). The NuRD complex is comprised of six 
core subunits, including HDAC1 and HDAC2 (531).  Although we present 
additional data showing that c-MYC and ID1 can also regulate MMP2 through the 
same region, these results appear to be indirect. It is possible that part of the 
actions observed when E2F is overexpressed could be due to upregulation of c-
MYC transcription, a known E2F target gene (532-534). Taken together, these 
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studies further our understanding of the link between the Rb-E2F cell cycle 
regulatory pathway to advanced stages of cancer development and metastasis.  
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Chapter 5: Nicotine stimulates the nAChR-Rb-E2F pathway to induce MMP 
transcription and metastasis in an orthotopic mouse model  
 
Abstract 
  Cigarette smoking is strongly correlated with the onset of non-small cell 
lung cancer (NSCLC). Nicotine, the addictive component of cigarettes, has been 
found to induce proliferation, confer resistance to apoptosis, and induce EMT like 
changes in breast, pancreatic, and lung cancer cell lines. In addition, nicotine 
also induces morphological changes characteristic of a migratory, mesenchymal 
phenotype in NSCLCs. At the same time, the exact molecular mechanism for this 
acquired invasiveness in NSCLCs has not been fully elucidated. To determine 
whether this increased invasion is due to up-regulation of matrix 
metalloproteinases, we examined the mRNA levels of matrix metalloproteinase 
genes after exposure to nicotine. MMP2, MMP9, MMP14, and MMP15 mRNA 
levels were significantly induced by treatment with nicotine when compared to 
serum starved A549 lung adenocarcinoma cells. Transient transfection 
experiments in H1650, A549, and MDA-MB-231 cell lines also showed that 
MMP-promoter luciferase reporters are all induced by treatment with nicotine. 
Further, nicotine could induce a stronger binding of E2F1 along with less Rb as 
seen in ChIP assays. Cells treated with nicotine and lacking E2F1 or E2F3 
showed a lower capacity for invasion compared to control. CCL-210 lung 
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fibroblasts had an increase in collagen degradation ability when treated with 
nicotine, and this was decreased when cells were treated with nAChR subunit 
inhibitors. In an orthotopic model of lung cancer metastasis, A549-luciferase cells 
lacking either E2F1 or E2F3 had less primary tumor growth and a decreased 
capacity for metastasis to the brain or liver after treatment with nicotine.  Taken 
together, MMP transcription is induced by nicotine treatment in lung cancer cell 
lines through the Rb-E2F pathway, and this pathway is required for lung cancer 
metastasis in an orthotopic mouse model. 
 
Introduction 
 Lung cancer is the leading cause of cancer in both men and women 
worldwide, and it is the most preventable type of cancer—the majority of lung 
cancers are associated with smoking (535, 536). Despite growing evidence 
showing a role for smoking with the initiation and progression of cancer, 30% of 
smokers diagnosed with lung cancer continue to smoke. Tobacco smoke 
contains multiple carcinogens such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) and N'-nitrosonornicotine (NNN), which can cause DNA adduct 
formation, mutation, and eventually oncogenesis (537).  While nicotine is the 
addictive component in cigarette smoke, it can’t initiate oncogenesis in humans 
or most rodent models—it only initiates tumors in hamsters (538). On the 
molecular level, it is becoming increasingly clear that signaling events associated 
with smoking are contributing to the growth, progression and metastasis of a 
variety of cancers.  
  
141 
 
Nicotine exerts its cellular functions through nicotinic acetylcholine 
receptors (nAChRs), which are present on both neurons and a variety of non-
neuronal cells as well (539). nAChRs are pentameric proteins consisting of nine 
α subunits (α2–α10) and three β subunits (β2–β4) in neuronal cells (540) and 
form two groups including a heteromeric pentamer of α2–α6 and β2–β4, and the 
other being a homomeric pentamer of α7–α9 (541, 542). A third type, the non-
neuronal muscle type receptors are composed of either α1, β1, δ and γ subunits 
in the embryonic form, or as α1, β1, δ or ε subunits in the adult form (543). The 
finding that nAChRs are present on non-neuronal cells gave way to studies 
showing that nicotine could induce the proliferation of endothelial cells (42) and 
lung cancer cell lines (45). Nicotine can also act as a paracrine or autocrine 
growth regulator through the secretion of growth factors such as bFGF, TGF-α, 
VEGF, and PDGF (544).  
  The accepted dogma is that nicotine can exert its functions by initiating 
cell signaling cascades through binding to a subunit of the nAChR pentamer, 
particularly α7 (40). When nicotine binds to nAChRs, this leads to the recruitment 
of β-arrestin-1 and Src to the nicotinic receptors, followed by the activation of 
downstream signaling pathways such as the MAPK cascade and the Raf-1-Rb 
pathway (37). Later studies identified the key players mediating the mitogenic 
effects of nicotine to include β-arrestin-1 and the Src kinase, where both 
components are indispensable for nicotine-mediated activation of cell 
proliferation (48). This signaling event causes the recruitment of E2F1, Raf-1 and 
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Rb on E2F responsive proliferative promoters including cdc6, cdc25a, TS, and 
survivin.  
   
 While numerous studies suggest a role for nAChRs in tumor growth and 
angiogenesis, there are fewer studies linking nAChRs to later stage tumor events 
such as EMT and metastasis. We had previously shown that in a panel of cell 
lines, nicotine exposure could induce EMT, invasion and migration in vitro (41). 
Further, nicotine could induce the Src-c-MYC-ID1-ZPB89 pathway to induce 
vimentin and fibronectin, conferring a more metastatic phenotype in lung cancer 
cell lines (346). Nicotine could also promote the metastic growth and tumor 
recurrence in an immunocompetent mouse model of lung cancer (51). Other 
studies had linked the proangiogenic activity of nicotine to the upregulation of 
MMP2 and MMP9 in retinal models of angiogenesis (523). These studies were 
aimed to further explore the biology of nicotine-induced metastasis. Nicotine 
could induce the expression of key invasion promoting genes, MMP2, MMP9, 
MMP14, and MMP15. We found that the Rb-E2F pathway regulated these 
genes. Further, E2F and subunits of nAChRs were required for nicotine induced 
collagen degradation, invasion, and metastasis to the brain and liver in an 
orthotopic model of NSCLC.  
Results 
Nicotine Induces MMP gene transcription in cell lines 
  To determine the effects of nicotine exposure on the expression of 
MMP gene transcription, H1650, A549, and MDA-MB-231 cell lines were 
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transfected with the exogenous MMP9-luciferase reporter along with the pRL 
construct and empty vector for normalization of transfection. Twelve hours after 
transfection, cells were treated with 1 µM nicotine for 24 - 48 hours, or placed in 
serum-free media as control. In all three cell lines, MMP9-luc was induced by 
treatment of nicotine alone (Figure 29A). To determine if the endogenous 
promoters are also induced by nicotine, A549 cells were serum starved for 18 
hours, and then kept in serum-free media, or in the presence of 1 µM nicotine for 
24 to 48 hours before total RNA was collected from cells. qRT-PCR was 
performed to analyze the effects of nicotine on the expression of MMP genes 
required for metastatic events. MMP2, MMP9, MMP14, and MMP15 RNA levels 
were all induced by treatment with nicotine (Figure 29B).  
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Figure 29. MMP genes are induced by nicotine in multiple cell lines. (A) H1650, A549, 
and MDA-MB-231 cells were transfected with MMP9-luciferase containing the MMP9 5’ 
promoter DNA, in addition to pRL containing the luciferase gene from Renilla reniformis 
for quantification of relative luciferase. In all cases, the MMP9-luciferase construct was 
induced by nicotine at 24 hours, but further by 48 hours. (B) A549 cells were made 
quiescent by serum starvation for 18 hours, followed by treatment with nicotine for 24 or 
48 hours. The mRNA levels of MMP2, MMP9, MMP14 and MMP15 were all induced at 
both time points after treatment with nicotine.  
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Nicotine induces MMP-luc activity and collagen degradation via nAChRs 
 We had previously shown that the α7 subunit of nAChRs were required for 
proliferation in a panel of lung cancer cell lines and to mediate the induction of 
ID1 (37, 346). To further understand the biological mechanism mediating the 
induction of MMP-promoters, we wanted to examine the effects of inhibiting 
various components of nAChRs. A549 cells were first transfected with MMP2, 
MMP9, or MMP14 luciferase constructs along with pRL, and then treated with 
either nicotine alone, or nicotine in the presence of indicated inhibitors. The 
general nAChR antagonist hexamethonium bromide (HBR) and the α7 specific 
inhibitor, alpha bungarotoxin (α-BT), inhibited the nicotine-mediated induction of 
all three promoter constructs (Figure 30A).  Contrasting to observations seen 
with proliferation assays, using the α3β2 and α4β2-subunit inhibitor dihydro β-
erythoidine (DHβE) and the muscarinic subunit inhibitor, atropine, could also 
inhibit the induction of MMP-luciferase activity. Given that these inhibitors could 
inhibit MMP RLA, we next performed collagen degradation assays to test if the 
biological functions of MMPs were also affected. Using any of the subunit 
inhibitors was effective at inhibiting nicotine-mediated collagen degradation 
(Figure 30B). This suggests that MMP transcription and collagen degradation can 
be induced by nicotine through multiple nAChR subunits, and might also be 
induced through the closely related muscarinic acetylcholine receptors as well.  
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Figure 30. Nicotine induces MMP-luc activity and collagen degradation via nAChRs. (A) 
A549 cells were transfected with MMP2-luc, MMP9-luc, and MMP14-luc constructs, 
each containing the 5’ promoter DNA sequence for their respective genes. Eighteen 
hours after transfection, cells were treated with nicotine alone, or nicotine along with the 
indicated nAChR inhibitors. Using each inhibitor was able to repress MMP RLA. (B) 
Collagen degradation assays were conducted on CCL-210 normal lung fibroblast cells. 
The use of any nAChR inhibitor could abrogate collagen degradation.  
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Nicotine induces MMP transcription and invasion through E2Fs 
 Previous studies had shown that nicotine could induce migration, invasion 
and EMT in vitro (37, 41). The MMP family is responsible for the degradation of 
the surrounding extracellular matrix, a crucial process for several stages of 
metastasis. Further, we had demonstrated that the MMPs responsible for these 
processes, MMP2, MMP9, MMP14, and MMP15 are E2F target genes (Chapter 
4 and 448). We created A549 cells that stably express an shRNA targeting E2F1, 
E2F3, or a non-targeting control ShRNA. Using these cells, we performed 
invasion assays with 20% serum as chemoattractant. Cells that were depleted of 
either E2F1 or E2F3 could not respond to nicotine for the induction of invasion in 
vitro (Figure 31A). Next, we conducted ChIP assays on A549 cells that were 
either serum starved or treated with nicotine for 48 hours (Figure 31B). Using 
antibodies against Rb and E2F1, we observed that when A549 cells were treated 
with nicotine, Rb was recruited to MMP9, MMP14, or MMP15 to a much lower 
level than serum starved control cells. This suggests that Rb was phosphorylated 
and inactivated upon nicotine stimulation, corresponding with previous studies on 
proliferative promoters (37). On the MMP14 promoter, the loss of Rb was also 
correlated with a stronger recruitment of E2F1, suggesting that this promoter is 
also more active upon nicotine stimulation. The MMP2 promoter appeared to 
have no change in Rb recruitment; however E2F levels were slightly decreased 
(Figure 31B). Given that E2F1 appeared to be a repressor of MMP2, it is logical 
that nicotine treatment would result in the dissociation of a repressor to yield an 
activation of transcription.  
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 Since nicotine could not induce invasion in the absence of either E2F1, or 
E2F3, and nicotine modulates Rb and E2F recruitment to MMP promoters, we 
next examined the effects of nicotine treatment on transcription of MMPs when 
E2Fs were depleted. Using two separate clones of A549 cells stably expressing 
shRNA targeting E2F3 or a non-targeting control vector, cells were made 
quiescent by serum starvation, then either kept in serum-free media or treated 
with 1 µM nicotine for 24 or 48 hours before RNA was collected. qRT-PCR 
results showed that when E2F3 was depleted, basal MMP2 mRNA levels were 
induced (lane 1 compared to lane 4 and 7) (Figure 31C). In addition, compared to 
the basal levels, there was no further induction of MMP2 mRNA after treatment 
with nicotine (lane 4 compared to lane 5 and 6; lane 7 compared to 8 and 9). This 
suggests that E2F3 was required for induction of MMP2 by nicotine. In A549 cells 
expressing the non-targeting shRNA, MMP9, MMP14, and MMP15 levels were 
all induced by nicotine as predicted (Figure 31D). Correlating with previous data 
showing that E2F3 depletion by siRNA decreased mRNA levels of MMP9, 
MMP14, and MMP15 (448), the A549 cells stably transfected with shRNA 
targeting E2F3 also had less basal expression of MMP9, MMP14, and MMP15 
(lane 1 compared to lane 4 and 7). In addition, compared to the basal levels, 
there was no further induction of MMP9, MMP14, or MMP15 mRNA after 
treatment with nicotine (lane 4 compared to lane 5 and 6; lane 7 compared to 8 
and 9) (Figure 31D). This suggests that E2F3 was required for induction of 
MMP9, MMP14, and MMP15 by nicotine as well. 
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Figure 31. Nicotine induces MMP transcription and invasion through E2Fs. (A) A549 
cells stably expressing shRNA targeting E2F1, E2F3 or a non-targeting control were 
used for invasion assays. Cells lacking E2F1 or E2F3 did not respond to nicotine, 
whereas control cells had 2-fold more invasion. (B) A549 cells were either serum 
starved, or treated with nicotine for 48 hours, and then ChIP assays were preformed. 
Nicotine promoted the dissociation of Rb from MMP9, MMP14, and MMP15 promoters, 
with a slight enhanced binding of E2F1 on the MMP14 promoter, whereas the MMP2 
promoter had less E2F1 binding after nicotine treatment. (C-D) qRT-PCR was used to 
examine MMP2, MMP9, MMP14, and MMP15 RNA levels after treatment with nicotine. 
E2F3 was required for nicotine-mediated induction of MMP gene transcription.  
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Nicotine promotes growth of A549-luc cells in an E2F-dependent manner 
  Previous studies had shown that nicotine could promote growth, 
metastasis, and tumor recurrence in an immunocompetent mouse model of lung 
cancer (51). Given that the induction of MMP gene transcription, invasion, and 
collagen degradation mediated by nicotine required E2Fs, we next studied the 
effect of depleting E2F1 and E2F3 in an orthotopic model of lung cancer. SCID-
beige mice (Charles River Laboratory) were surgically implanted with 250,000 
A549 cells stably expressing the firefly luciferase gene (A549-luc) (Caliper) 
directly into the right lung.  Six hours following surgery, animals were 
randomized, and then implantation of the tumor in the lungs was monitored using 
the Caliper-IVIS 200 system after administration of luciferin. Mice were imaged 
once per week, and treated with 1 mg/Kg nicotine in 100 µL PBS, or the PBS 
control thrice weekly. At the end of the experiment, animals underwent extensive 
necropsy and vital organs were separately imaged to identify nodes of 
metastasis (Figure 32) Nicotine treatment significantly enhanced the lung 
bioluminescence (Figure 33B). Further, cells depleted of E2F1 or E2F3 had less 
bioluminescence than the controls and did not respond to nicotine treatment 
(Figure 33A-B). To confirm these observations seen in vivo, lung 
bioluminescence was examined ex vivo. Mice treated with nicotine had more 
lung bioluminescence (Figure 33C-D), indicating that the injection was localized 
to the lungs, and not disseminated into the pleura. In addition, cells depleted of 
E2F1 and E2F3 had less bioluminescence ex vivo as well.  
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Figure 32. Schematic representation of an orthotopic model of lung cancer metastasis.  
SCID-beige mice are given a 100 µL injection of 250,000 cells directly into the right lung. 
Mice are randomized, then treated thrice weekly for five weeks either with PBS or 1 
mg/Kg nicotine by intraperitoneal injection. At the completion of the study, mice were 
anesthetized, and the brain, liver, and lungs were imaged ex vivo for the identification of 
smaller regions of bioluminescence, being indicative of micrometastases. These signals 
were quenched in vivo due to the bright primary tumor signal in the lung.  
+ Nicotine 
+ PBS 
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Figure 33. Nicotine promotes growth of A549-luc cells in an E2F-dependent manner in 
vivo. (A-B) A549-luc cells were implanted into  the lung of SCID-beige mice, and mice 
were imaged once per week for five weeks. Image of total lung bioluminescence at day 
35. Data were quantified and P-values were calculated for Sh E2F1 (*P=0.013) and Sh 
E2F3 (*P=0.014) groups treated with nicotine compared to Sh Control group treated with 
nicotine. (C-D) Lungs were removed from animals during routine necropsy and imaged 
ex vivo to ensure that observed signal in the mouse was due to efficient implantation of 
cells into the lung rather than the pleural cavity. Mice treated with nicotine had an 
increase in bioluminescence compared to the control. Cells lacking E2F1 or E2F3 could 
not respond to nicotine.  
A B 
D C 
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Nicotine promotes metastasis of A549-luc cells in an E2F-dependent 
manner 
 To determine if nicotine promoted metastasis to other organs, we performed 
routine necropsy of mice at the termination of the experiment. The brain, liver 
and lungs of each mouse were imaged separately within fifteen minutes post 
mortem using the Caliper-IVIS system. Organs were placed in 30 mg/Kg luciferin 
in a 60 mm tissue culture dish, and then images were taken at 1 second 
exposure. Animals implanted with the A549-luc cells with Sh control vector and 
treated with nicotine had the highest number of overall metastases, having 5/6 
mice with brain metastasis, and 6/6 mice with liver metastasis. The PBS treated 
control mice had significantly less brain metastasis, 1/6, but still a fair amount of 
liver metastasis at 50% (Figure 34A-B). This is interesting due to the temporal 
regulation of metastasis in humans as well, where brain metastasis occurs after 
long periods of latency (545). Further, the Sh E2F1 group that was treated with 
PBS had more liver (4/6) and brain metastasis (2/6) than controls, however the 
nicotine treated Sh E2F1 group did not have the induction of metastasis 
observed in the nicotine treated Sh control group (5/10 liver; 1/10 brain). Mice 
implanted with Sh E2F3 cells did not have any observable metastasis in the brain 
in both groups, and the least amount of liver metastasis out of the three groups 
(1/6 liver mets in PBS group; 2/6 liver mets in nicotine group). These data 
suggest that E2Fs are required for the metastatic dissemination of lung cancer 
cells in response to nicotine, and that E2F3 might play a major role in growth and 
metastasis.  
  
154 
 
 
Figure 34. Nicotine promotes metastasis of A549-luc cells in an E2F-dependent 
manner. (A-B) Mice implanted with either Sh Control, Sh E2F1, or Sh E2F3 cells were 
subjected to routine necropsy, then brains and livers were imaged ex vivo.  Mice with Sh 
Control tumors when treated with nicotine had many more brain metastases than the 
PBS group. Further, mice lacking either E2F1 or E2F3 did not respond to nicotine, and 
had far less brain metastasis than controls.  
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Discussion 
 Given the significant role that MMPs play in pathological conditions, the 
exact biological substrates for MMPs in the metastatic process are still poorly 
understood. MMP2 and MMP9 are the traditional gelatinases, being able to 
degrade gelatin and type IV collagen (314). These MMPs are both secreted into 
the pericellular space, and can also function through the activation of latent 
growth signals (546). This would further explain how nicotine could enhance 
proliferation of cells orthotopically implanted, as well as affecting the metastatic 
dissemination. Further, MMP14 is a type I collagenase, and is tethered to the cell 
surface. Numerous studies have demonstrated that MMP14 is the most crucial 
protease for metastasis (294, 324, 434).  The biological functions of MMP15 are 
still less clear, however it is structurally similar to MMP14, and had been shown 
to impart an invasive phenotype in certain tumor types (547-549). MMP15 could 
also make cells resistant to apoptosis, which indirectly promoted cells escaping 
from the primary tumor and traveling to the distant site (550).  
 
 Prior work demonstrated that proliferative signaling via the nAChRs induced 
the dissociation of Rb from E2F1 (37). The Rb-E2F pathway is deregulated in 
about 90% of lung cancers, suggesting a critical role for these proteins in 
maintaining a normal cell phenotype (551). Further, inactivation of Rb by gene 
mutation or hyperphosphorylation caused it to dissociate from E2Fs. The free 
E2Fs could then bind to specific E2F-binding sites on the promoters of 
proliferative genes like cdc6, cdc25a, TS, and others, thereby stimulating 
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transcription leading to S-phase entry (552).  In addition, there is evidence that 
E2F family members themselves have gene amplification, increased expression, 
or mutation in a variety of cancers, including NSCLC (553-555).  However a 
correlation between E2F protein levels and advanced staged cancers has yet to 
be made.  
 
 These studies show that cancer cells activate metastasis genes such as 
MMP2, MMP9, MMP14, and MMP15 by utilizing similar mechanisms that control 
proliferative gene expression in response to nicotine.  Further, since multiple E2F 
family members are known to regulate the basal expression of MMP genes 
(448), it is possible that multiple E2F family members can also mediate the 
effects of nicotine. Depletion of E2F1 or E2F3 had a significant effect on the 
growth of primary tumors implanted into the lungs of mice, but it also completely 
abrogated the effects of nicotine-induced metastasis.  We had previously 
demonstrated that β-arrestin-1 is required to mediate the effects of nicotine at 
proliferative promoters. In that study, β-arrestin-1 facilitated the acetylation of 
histones in NSCLCs in response to nicotine, however the acetylation of key 
transcription factors has not yet been tested. E2F1 can be acetylated, and the 
acetylation of E2F1 can make it bind to DNA more strongly (556).  It seems likely 
that β-arrestin-1 might also regulate the expression of MMP genes in response to 
nicotine, and might also regulate the acetylation of E2F1 at these promoters. Src 
was also required for mediating the effects of the nicotine-β-arrestin-1 signaling 
cascade. In addition, Src had been shown to elicit an NNK mediated protein 
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kinase cascade as well, resulting in increased migration and invasion of human 
lung cancer cells (557). The signaling events between nicotine binding to 
nAChRs, and then E2Fs regulating MMP genes remain unclear, but may also 
involve Src.  
 
 It is possible that E2F family members are regulating other genes involved 
in metastasis. Previous studies in mouse models demonstrated that tumors 
harvested from nicotine treated mice had lower levels of E-cadherin and ZO-1 
throughout the tumor (51). Further, we had demonstrated in vitro that treatment 
with nicotine can induce EMT changes such as a gain of vimentin expression and 
loss of E-cadherin, invasion and migration in a panel of cell lines (41). Further, it 
had been reported that the expression pattern of nAChR subunits are different in 
tumors from smokers and non-smokers (558). Given the ability of nicotine to 
promote MMP transcription and collagen degradation through multiple subunits 
of nAChRs, it is possible that general antagonists of nAChR signaling might 
prove beneficial in controlling metastasis of lung cancers as well.   
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Summary and Conclusions 
 
 Nearly two decades after the discovery of a link between E2F activity and 
cell cycle control, there is new evidence linking the Rb-E2F pathway to nearly all 
hallmarks of tumorigenesis (264). It is believed that the strongest mechanism that 
Rb utilizes to regulate the cell cycle is though its inhibitory interaction with E2F 
transcription factors. As a cell moves through the cell cycle from G1 to S phase, 
Rb is hyperphosphorylated by a variety of kinases, particularly cyclin D and cyclin 
E-associated kinases, inactivating the Rb protein, and it is subsequently released 
from E2F transcription factors. Rb does not work alone, however, and also 
utilizes its pocket protein family members, p107 and p130, to stringently regulate 
gene expression (8). The E2F family encodes ten transcription factors, and of 
these members only E2F4 can interact with all the pocket proteins. Indeed, it is 
the interaction between inhibitory E2F4 and E2F5 with p107 and p130 that keeps 
cells in a quiescent state until mitogenic stimulation initiates the cell cycle.   
 
 Not surprisingly, the Rb-E2F pathway is a critical target in a variety of 
cancer types (124, 449). At the level of growth factors and growth factor 
receptors, a variety of mutations are observed in both solid tumors and 
hematapoietic malignancies, including HER2 amplification in breast cancer and 
the famous Philadelphia chromosome, BCR-ABL in chronic mylegenous 
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leukemia (559, 560). At the front of the intracellular portion of growth factor 
receptors, key kinases, such as K-Ras and Src are tethered into the hydrophobic 
lipid bilayer and act as mediators of extracellular signals (561, 562). It is well-
known that these genes can also be mutated in cancers. Other downstream 
molecules such as cyclins and Cdks are also mutated in cancer; famously, in 
breast cancer cyclin D is overexpressed (563). All these mutations impact the 
readout of the Rb-E2F pathway. Further, mutations of Rb are found in a variety of 
cancers, and this has also been correlated with the overexpression of several 
E2F family members in certain cancers; E2F transcription factors are 
overexpressed in a portion of cancers with wild type Rb as well (66).  
 
  We had previously demonstrated that Rb can also be inactivated by an 
additional, non cyclin-dependent kinases, Raf-1, or c-RAF (36). When this 
interaction was inhibited in lung cancer, there was less proliferation, 
angiogenesis, and tumor growth. We now show that the Rb-Raf-1 interaction is 
also required for lung colonization in an in vivo model of metastasis. Further, 
when E2Fs were depleted, collagen degradation, invasion, and migration were all 
abrogated; MMPs are the essential regulators of all of these processes. These 
processes were also inhibited when the Rb-Raf-1 interaction was inhibited with 
RRD-251. Nicotine can stimulate the interaction of Raf-1 with Rb, leading to 
eventual inactivation of Rb, and ungoverned E2F activity at target gene 
promoters (38).  Our findings show that the downstream effects of Rb and E2F at 
MMP promoters require multiple subunits of nAChRs and multiple E2F family 
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members. Future in vivo experiments could reveal whether blocking the Rb-Raf-1 
interaction is also effective at inhibiting lung metastasis. These studies along with 
other in vivo models could open the door to developing novel therapeutics for 
treatment of NSCLC.  
 
 In the multi-step model of cancer, the development and progression of the 
disease is similar to Darwinian evolution. Cancer cells require advantages 
genotypes to promote survival and proliferation: where rare precursor cells (or 
cancer stem cells) will eventually, after many clonal selections, give rise to a 
virulent tumor cell population. In this model of selection, the propensity to 
metastasize is a rare trait that is acquired later, possibly after the tumor has 
reached critical mass.  Given that metastasis is indeed a rare event, and that 
even cells which have entered circulation do not have a high likelihood to survive, 
this model begs the question: How can metastasis ever proceed? 
 
 Studies presented here suggest a differing model of metastasis, where the 
same proteins that conferred a proliferative advantage in early stages of disease 
also contribute to metastatic dissemination—the genetic abnormalities required 
for early stages promote the later dissemination and growth.  The decision for 
cells to metastasize is not made until additional mutations are present or signals 
are received that would aid cells in their journey to a new site. This suggests that 
genes that are involved in oncogenesis might have overlapping functions in 
promoting metastasis, making it difficult to compartmentalize genes as sole 
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regulators of initiation or metastasis. Thus, growth promoting gene families, such 
as the E2Fs, might be master regulators of every stage of progression. The E2F 
family is known to regulate proliferation, angiogenesis, apoptosis, DNA damage 
repair, differentiation, and now metastasis. This could also explain how small cell 
populations can metastasize; for example small primary breast cancers can 
display detectable cells in the bone marrow (564). Further, although elegant 
microarray studies have identified genes that are different in metastatic 
populations, what is lacking from these discussions is that aside from the handful 
of genes identified, the remainder of the genotype is nearly identical between 
primary tumors and metastatic tumors. In addition to the E2F family, other key 
oncogenes with known roles in proliferation have also been shown to enable 
metastatic spread, including cyclin D1, c-MYC and RAS (498, 565-571). Genes 
which are required for normal cell division, and not considered oncogenes, have 
also been implicated in metastasis such as EGR1 and Sp1 (572-574). Taken 
together, although a large effort has been made to understand the differences 
between primary tumors and metastasized tumors, targeting the similarities might 
prove to be a more efficient strategy for treating cancer patients irrespective of 
the stage of their disease.  Further, we believe that a significant amount of 
additional studies on the pathways that govern tumor initiation, progression and 
metastasis would be necessary to develop therapeutic strategies that will combat 
cancer effectively. 
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